Companies news of 2009-09-16 (page 10)

  • Savient Provides Update on Meeting with U.S. Food and Drug Administration for...
  • Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through...
  • GENova and TheraGlass in advanced negotiations
  • SectorWatch.biz Issues MarketStats on Water Treatment and Environmental Waste Companies...
  • UMC First to Announce Carbon Footprint Verification on Integrated Circuit Wafers
  • Evolution Petroleum Reports Fiscal 2009 Fourth Quarter and Year-End Financial Results
  • Newpark Resources Announces Third Quarter 2009 Earnings Release and Conference Call...
  • Polaris Software Launches Intellect GUB CBX at Sibos
  • Charge Into Fall with Fresh Updates for the HomeLighting, Textures and Colors Change the...
  • The re3 Concept: Triple Symbiosis Between Form, Function and Finesse
  • Aricent and Cavium Networks Collaborate to Provide LTE Evolved Packet Core SolutionsJoint...
  • Forterus Inc. Launches Updated, Improved Web Site
  • Autonomy Applies its Advanced Meaning-based Technology to Transform Database...
  • Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan
  • Epson PowerLite Pro Cinema 9100 Wins CustomRetailer 2009 EXC!TE AwardHigh-Performing 1080p...
  • easypod(R), dispositif d'injection de l'hormone de croissance de Merck Serono, approuvé au...
  • 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or...
  • Cell Therapeutics, Inc.'s (CTI) Presentation at BioCentury NewsMakers Conference to be...
  • GENova Biotherapeutics forming academic partnerships
  • Prepare for an All-Out Assault With Xbox 360 Modern Warfare 2(R) Limited Edition...
  • Federal Court Sides With Industry Icon Karl W. Miller, Dismissing With Prejudice All...
  • Harry Winston Diamond Corporation announces Diavik Diamond Mine cancels winter production...
  • Fannie Mae annonce les résultats des enchères de la réouverture des obligations Benchmark...
  • Microsoft and M-Com Deliver Mobile Payments Solution Globally
  • CBp Carbon Industries Announces Pre-Commercial Production for Its First Commercial Plant...
  • Vista Gold Corp. Announces Pricing of Common Stock Offering
  • Microsoft and M-Com Deliver Mobile Payments Solution GloballyLeading mobile banking...
  • CBp Carbon Industries Announces Pre-Commercial Production for Its First Commercial Plant...
  • Multiplied Media's Poynt mobile local search application surpasses 1,000,000 users
  • Payless ShoeSource Unveils Spring '10 Designer Collections on the Runway at New York...



    Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)Company Confirms Early 2010 Target for KRYSTEXXA Resubmission

    EAST BRUNSWICK, N.J. Sept. 16 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. today announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.

    Based on the results of this meeting with the FDA, Savient believes that the FDA supports its approach to resolve all issues cited in the CRL. The meeting also confirmed that the FDA does not expect further clinical trials to be required as a result of Savient's reversion to the original manufacturing process to produce the Phase 3 clinical trial material for KRYSTEXXA, provided that no significant differences are observed between the material produced with the validated Phase 3 process and the Phase 3 clinical trial material. Savient, therefore, continues to believe that it can meet its previously discussed timeline of filing the resubmission in response to the CRL in early 2010.

    "We are encouraged by the FDA's continuing collegial and collaborative dialogue in providing guidance to assist us in establishing the path forward to our resubmission for KRYSTEXXA," stated Paul Hamelin, President of Savient Pharmaceuticals. "We are grateful to the FDA for granting us this meeting so quickly and appreciate the considerable time and effort devoted by the FDA reviewers in evaluating our pre-meeting package and in providing very valuable feedback and guidance."

    In response to the CRL, Savient requested and was granted the Type A meeting with the FDA to discuss, clarify and reach alignment on a resubmission plan to fully address all deficiencies and issues identified in the CRL. The FDA indicated that, in its view, Savient's plan to revert to and validate the original manufacturing process used to produce the Phase 3 clinical trials material, together with the inclusion of additional 0.22 micron filters in the manufacturing process, is a reasonable approach that the FDA expects will produce drug substance that is representative of that used in the pivotal Phase 3 clinical trials. The FDA stated that it also expects that the comparability between material produced with the validated Phase 3 process and the Phase 3 clinical trial material used in the replicate clinical trials to establish safety and efficacy can be sufficiently established by quality criteria alone without the need to conduct additional clinical studies, provided no significant differences between products are observed.

    The FDA also agreed at this meeting with the methods and criteria proposed by Savient to tighten manufacturing analytical methods and acceptance criteria for all manufacturing steps in the final commercial production process. However, some of these final analytical methods and acceptance criteria are subject to being set based upon the data from historical manufacturing and validation batches that will be included in the resubmission. The meeting outcomes confirm Savient's belief that it is on track to meet its previously discussed timeline of filing the resubmission in response to the CRL in early 2010.

    The FDA also provided additional clarity relating to the steps necessary for Savient's drug substance manufacturer, Bio-Technology General (Israel) Ltd (BTG), a subsidiary of Ferring Pharmaceuticals, to satisfactorily correct the observations cited by the FDA during its pre-approval inspection of the BTG manufacturing facility. Savient believes that BTG's remediation of these observations can be corrected ahead of its resubmission to the FDA in response to the CRL.

    The FDA also stated that the format and content of Savient's proposed safety update, which will include additional data collected from the KRYSTEXXA Open Label Extension study, is acceptable to the FDA.

    During the meeting, the Company was informed that the review cycle for the resubmission would include the review of all data to fully address all issues identified in the CRL, including the final product labeling and the REMS materials. Since the resubmission will include REMS materials, this is subject to a Class 2 review cycle, meaning simultaneous approval of all components of our filing within six months of the date of our resubmission.

    "We look forward to continuing to work with the FDA and executing on our resubmission strategy to the Complete Response Letter so that we can move forward with delivering this important therapy to treat chronic gout patients who are suffering from this crippling, debilitating disease and who have no other treatment options," commented Mr. Hamelin.

    Savient also stated that the official minutes of this Type A meeting with the FDA will be made available to the Company within approximately 30 days from the date of the meeting.

    Conference Call Information

    Savient's management team will host a live conference call and Webcast today at 9:00 a.m. Eastern Time/6:00 a.m. Pacific Time to further discuss the results of the Type A meeting with the FDA. To participate by telephone, please dial 888-349-9587 from the U.S. or 719-457-2640 for international callers. The conference identification number is 8540659. The live and archived Webcast can be accessed on the investor relations section of the Savient Website at http://www.savient.com/. Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

    ABOUT KRYSTEXXA(TM)

    KRYSTEXXA(TM) (pegloticase) is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

    ABOUT SAVIENT PHARMACEUTICALS, INC.

    Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com/. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

    FORWARD-LOOKING LANGUAGE

    All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase), whether any further clinical trials will be required, the actions that may be required of Savient by the FDA in connection with the BLA, the reversion to and revalidation of the Phase 3 manufacturing process, the timing of a resubmission to the FDA in response to the complete response letter and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials, our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

    SVNT-G

    Savient Pharmaceuticals, Inc.

    CONTACT: Mary Coleman of Savient Pharmaceuticals, Inc., +1-732-418-9300,
    information@savient.com, or Susan Neath of Burns McClellan, +1-212-213-0006,
    sneath@burnsmc.com

    Web Site: http://www.savient.com/




    Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through Alliance with Optasia

    BOSTON, Sept. 16 /PRNewswire-FirstCall/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation , today announced that it has enhanced its capabilities to provide medical imaging measurements for osteoarthritis clinical trials through an alliance with Optasia Medical, Inc. Perceptive Informatics is using Optasia's KneeAnalyzer(TM) software to supplement its existing medical imaging technology to improve the reproducibility of and reduce the time involved with image analysis of the knee in osteoarthritis patients.

    "Medical imaging plays an important role in the early evaluation of new compounds in musculoskeletal related clinical research, including in the growing areas of rheumatoid arthritis, osteoporosis, and osteoarthritis," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics. "Our alliance with Optasia provides customers with better surrogate measurements in trials focused on knee-related osteoarthritis, a progressive disease. This relationship represents our commitment to help customers accelerate trials and speed new treatments to patients in the musculoskeletal therapeutic area."

    Optasia develops software, which issued in clinical trials to identify and monitor patients who will benefit from treatment, to facilitate the more rapid, accurate evaluation of medical images with greater reproducibility. Optasia's software applications are based on the Optasia Platform, which employs model-based vision technology to detect, measure, classify and compare two-dimensional medical images.

    Perceptive Informatics has a broad range of musculoskeletal imaging clinical research experience and capabilities. The Medical Imaging Group of Perceptive Informatics offers a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology.

    About Perceptive Informatics

    Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: http://www.perceptive.com/.

    About PAREXEL International

    PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,275 employees. For more information about PAREXEL International visit http://www.parexel.com/.

    This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts: Jennifer Baird, Senior Director Gene Carozza/Kim Baker of Public Relations PAREXEL International PAN Communications Tel: +781-434-4409 Tel: +978-474-1900 Email: Jennifer.Baird@PAREXEL.com Email: PAREXEL@pancomm.com

    PAREXEL International Corporation

    CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
    International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Gene Carozza or
    Kim Baker, both of PAN Communications for PAREXEL International,
    +1-978-474-1900, PAREXEL@pancomm.com

    Web Site: http://www.parexel.com/




    GENova and TheraGlass in advanced negotiations

    NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- (OTCBB: GVBP.OB.) - GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

    TheraGlass, classified as a medical device, interacts with the body's tissues to stimulate cell growth and provide vital anti-bacterial, structural, and regenerative proteins. It is entirely non-toxic and is reabsorbed and excreted through the body's natural metabolic processes.

    The two companies are already actively exploring the possibilities and opportunities of combining TheraGlass IP with GENova's drug targets; which will create a brand new class of blockbuster therapeutic drugs for the treatment of cancer. This advancement is potentially worth significant amounts in royalty payments should GENova be successful in creating this new class of drug treatment.

    The two companies have entered into an LOI for GENova to acquire a number of TheraGlass Ltd's patents, the deal is expected to close in Q4 and will see GENova significantly increase its overall value of its IP portfolio and thereby move closer to position itself as a possible takeover target for a major pharmaceutical company.

    "The potential for augmenting cancer treatments with a regenerative product like TheraGlass is tremendous," says GENova CEO Aaron Whiteman. "While GENova's treatments destroy cancerous cells, TheraGlass can stimulate healthy cells to regenerate, thus expediting the healing process."

    The two companies are mapping out the deal and plan on making the details of that deal public in the coming weeks.

    About TheraGlass Ltd.

    TheraGlass Ltd. has an exclusive international position for the commercialisation of sol-gel derived bioactive glass under the trade name TheraGlass. Discovered by Professor Larry Hench and developed at Imperial College London, TheraGlass is the next generation of bioactive glass, a medical device material that can interact with the body's hard and soft tissues to stimulate cell growth, accelerating the body's self healing properties. TheraGlass has potential uses in diverse fields including as a replacement for autologous (i.e. self donor) bone grafts, 3D craniofacial reconstruction, the replacement of collagen sponges, as a tissue engineering scaffold (seeded with stem cells), in wound treatments from battlefield dressings and bedsore to domestic first aid kits, in drug delivery, dental fillers, toothpaste to heal sensitive teeth, and even cosmetic applications.

    About GENova Biotherapeutics Inc.

    GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: http://www.genovabio.com/.

    Forward Looking Statements

    This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

    GENova Biotherapeutics, Inc.

    CONTACT: Investor Relations: Brian Cook, Windfall Communications LLC,
    1-866-797-8703, info@windfallcommunications.com




    SectorWatch.biz Issues MarketStats on Water Treatment and Environmental Waste Companies GEVI, NLC, AWK, VE, PLL and SHAW

    IRVINE, Calif., Sept. 16 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats for water treatment and environmental waste equities in the news and driving markets today. SectorWatch.biz offers a perspective on the aforementioned equities and the opportunity for investors to respond with articles, blogs and opinions.

    Investors can view MarketStats by visiting: http://www.sectorwatch.biz/ - in association with FiSpace.net, a dynamic social networking site for investors.

    Today's MarketStats for innovative water treatment and environmental waste companies include General Environmental Management, Inc. (BULLETIN BOARD: GEVI) , Nalco , American Water Works Company, Inc. , Veolia Environnement , Pall Corporation and Shaw Group Inc. .

    General Environmental Management, Inc. (GEM) recently announced that its board of directors had elected to shift its business focus from hazardous waste field services to the fast-growing water treatment and waste-to-energy markets.

    View a news-featured profile on GEM here:http://stockupticks.com/profiles/9-16-09.html

    GEM is a full-service hazardous waste management and environmental services firm providing integrated environmental solutions managed through its proprietary web-based enterprise software, GEMWare, including waste management, on-site waste treatment systems, management of large remediation projects, to environmental incident response, and environmental compliance.

    Learn more here: http://www.generalenvironmental.com/index.html

    Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.

    This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has contracted to be paid twelve thousand dollars by QualityStocks.net for preparation and distribution of this report and other advertising services over a thirty-day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company. MP's analyst, J. Knepp, holds CRD#2849651. To be featured in our publications please call the number below.

    Contact: Shannon Squyres, Editor Market Pathways /SectorWatch.biz 949-955-0107

    SectorWatch.biz

    CONTACT: Shannon Squyres, Editor of Market Pathways /SectorWatch.biz,
    +1-949-955-0107

    Web Site: http://www.sectorwatch.biz/




    UMC First to Announce Carbon Footprint Verification on Integrated Circuit Wafers

    HSINCHU, Taiwan, Sept. 16 /PRNewswire-Asia-FirstCall/ -- UMC ( TSE: 2303) , a leading global semiconductor foundry, today announced that it has completed the foundry industry's first reported carbon footprint verification for integrated circuit wafers produced at its facilities. UMC conducted carbon footprint inventory on its 200mm wafers at the company's Fab 8A according to international carbon footprint standard PAS2050, with the results receiving third party verification by Det Norske Veritas (DNV). UMC is the only semiconductor company in Taiwan that independently calculates, verifies, and reports carbon footprints for its products.

    Mr. Muh Liang Liao, vice president from UMC, said, "UMC has always paid special attention to the issue of climate change and has aggressively implemented comprehensive carbon management programs. Due to the advanced technologies and numerous materials involved in the manufacturing of semiconductor wafers, carbon footprint calculation is quite complicated. Since UMC started its product life cycle assessment in all fabs in 2005, we were able to complete this verification in the shortest time possible. The result is a significant milestone for UMC's development in green production. This verification provides complete, scientific and reliable disclosure on the carbon information of products manufactured in our fabs as well as self-review on environmental impact. Moreover, it is a demonstration of UMC's social responsibility to practice transparent communication with our stakeholders."

    UMC's comprehensive carbon management program includes energy-saving and carbon reduction measures with priority on reducing carbon in the manufacturing processes. UMC led the foundry industry to complete the replacement of C2F6 with lower GWP C3F8 in 2007. This replacement program helped reduce CO2 emissions by 410,000 metric tons in 2008, a reduction of around 25% of UMC's total CO2 emissions. Furthermore, UMC's introduction of C4F8 in 2008 further enhanced UMC's carbon reduction with more efficient CO2 reduction. UMC also believes in the importance of timely disclosure of carbon information and ensuring data quality. Since 2006, UMC has participated in the Carbon Disclosure Project (CDP) formed by global institutional investors, disclosing UMC's annual greenhouse gas emission volume, reduction goals and results. Moreover, UMC adopts third-party verifiers to ensure the quality of data. UMC completed verification on greenhouse gas emissions and reduction from 2000 to 2008 for all of our Taiwan fabs, with efforts ongoing every year.

    Carbon footprint verification serves as the basis for UMC to further promote green products, green manufacturing processes and green design. Going forward, UMC is committed to advance carbon management in a more practical way and to fulfill the responsibility as a corporate citizen by reducing CO2 more aggressively.

    About UMC

    UMC is a leading global semiconductor foundry that provides advanced technology and manufacturing services for applications spanning every major sector of the IC industry. UMC's customer-driven foundry solutions allow chip designers to leverage the strength of the company's leading-edge processes, which include production proven 65nm, 45/40nm, mixed signal/RFCMOS, and a wide range of specialty technologies. Production is supported through 10 wafer manufacturing facilities that include two advanced 300mm fabs; Fab 12A in Taiwan and Singapore-based Fab 12i are both in volume production for a variety of customer products. The company employs approximately 12,000 people worldwide and has offices in Taiwan, Japan, Singapore, Europe, and the United States. UMC can be found on the web at http://www.umc.com/

    Editorial Contacts: In the USA: UMC-USA Charlene Loveless Tel: +1-408-523-7850 Email: charlene.loveless@umc-usa.com In Taiwan: UMC Richard Yu Tel: +886-2-2700-6999 ext. 6951 Email: richard_yu@umc.com

    United Microelectronics Corporation

    CONTACT: In the USA, UMC-USA, Charlene Loveless, +1-408-523-7850,
    charlene.loveless@umc-usa.com ; In Taiwan, Richard Yu, +886-2-2700-6999 ext.
    6951, richard_yu@umc.com, both of UMC

    Web site: http://www.umc.com/




    Evolution Petroleum Reports Fiscal 2009 Fourth Quarter and Year-End Financial Results

    HOUSTON, Sept. 16 /PRNewswire-FirstCall/ -- Evolution Petroleum Corporation (NYSE Amex : EPM) today reported financial and operating results for the three month and twelve month periods ended June 30, 2009, the Company's fourth quarter ("Q4-09") and fiscal year-end ("FY-09").

    Fourth Quarter Results

    Oil and gas volumes for Q4-09 increased 17% to 31,639 barrels of oil equivalent ("BOE"), or 347.7 BOE per day, compared to the three months ended June 30, 2008 ("Q4-08"). Oil and gas revenues for Q4-09 were $1.0 million compared to $2.4 million for Q4-08, due to a 64% decline in blended oil and gas prices from $86.97 per BOE to $31.10 per BOE. The increase in volumes was the result of drilling and work-over operations in the Giddings Field in central Texas.

    Sequentially, volumes were 26% lower and revenues were 16% lower for Q4-09 compared to Q3-09, partly due to mechanical problems with the gas purchaser's compressor for the company's most significant well, which has been corrected, as well as normal production declines. The sequential revenue reduction was partially offset by a 14% improvement in the average sales price per BOE during Q4-09 due to higher oil prices, partially offset by lower natural gas prices.

    Net loss in Q4-09 was $0.7 million, or $(0.03) per share, compared to net income in Q4-08 of $0.4 million, or $0.01 per diluted share. Results for both periods included $0.55 million and $0.53 million, respectively, in non-cash depreciation, depletion and amortization, plus non-cash stock-based compensation expense of approximately $0.76 million and $0.48 million charged in Q4-09 and Q4-08, respectively.

    For Q4-09, Adjusted EBITDA (a non-GAAP measure including net interest income, but excluding non-cash items as reconciled below) was $0.2 million compared to $1.2 million in Q4-08.

    Working capital remained steady at $7.6 million on June 30, 2009, as compared to $7.5 million at March 31, 2009. Working capital at the end of Q4-09 included $6.0 million of cash, cash equivalents and short-term certificates of deposit, in addition to $2.1 million of income taxes recoverable arising from current year tax losses being carried back to a prior tax year. The company ended the year with no outstanding debt, and all capital expenditures during the year were funded from working capital.

    During the quarter ended June 30, 2009, the company incurred capital expenditures of $0.8 million for the acquisition and development of its oil and gas properties.

    Robert Herlin, President and Chief Executive Officer, commented, "With natural gas prices remaining low, we have shifted focus to our oil development project in South Texas, the Neptune infill drilling program. We plan to begin drilling our first two producers and one water injection well by the end of September. Thus far, we have invested approximately $0.6 million in Neptune, primarily to acquire leases in this field, which was fully plugged and abandoned years before the run-up in oil price in 2004. Our independent reserves engineer assigned 541 MBO of proved, probable and possible oil reserves with pre-tax PV-10 of $8.1 million associated with the first 25 proved and probable infill drilling locations, and we have identified an additional 79 prospective infill drilling locations on our leases. We believe the Neptune project is one more example of how we efficiently create value through low risk, low cost and repeatable drilling."

    Mr. Herlin further stated, "As previously announced, we are limiting our 2010 capital spending to a portion of our cash on hand and cash from operations. We expect to see cash flows from the Delhi Field in fiscal 2011 and should be positioned to increase our activity without having to substantially dilute our shareholders or take on risky, high cost debt. We believe that our portfolio of high-quality, low-cost projects allows us to create value for our shareholders without undue risk."

    Production Volumes and Prices:

    Net volumes for Q4-09 were 17,471 barrels ("Bbl") of oil, condensate and natural gas liquids ("NGL") and 85.0 million cubic feet of natural gas ("MMCF"), or 31,639 BOE. This is an increase of 17% over volumes for Q4-08 of 18,237 Bbls of oil, condensate and NGLs and 53.1 MMCF of natural gas, or 27,095 BOE. The average price of our oil fell 56% to $57.02 per barrel in Q4-09 from $130.69 per barrel in Q4-08, while the average price of our NGLs fell 57% in Q4-09 to $27.55 per barrel from $64.62 per barrel in Q4-08. The average price of our natural gas fell 67% to $3.42 per Mcf in Q4-09 versus $10.24 per Mcf in Q4-08. On a BOE basis, the blended effective price received declined 64% to $31.10 in Q4-09 from $86.97 in Q4-08, due in part to Q4-09 sales including a higher portion of natural gas.

    Costs and Expenses

    Lease operating expenses, including production severance taxes, for Q4-09 were $0.40 million ($12.59 per BOE) compared to $0.33 million ($12.11 per BOE) for Q4-08, due primarily to higher water disposal costs associated with the company's best well and reduced volumes due to third party-related downtime of that well. Depreciation, Depletion & Amortization Expense ("DD&A") was $0.55 million ($17.45 per BOE) for Q4-09 compared to $0.53 million ($19.58 per BOE) in Q4-08, due primarily to a reduction in projected capital expenditures associated with proved undeveloped locations.

    General and administrative ("G&A") expenses declined to $1.17 million for Q4-09, as compared to $1.43 million for Q4-08, due primarily to reduced year-end bonuses paid in company stock and reduced staff, offset by higher legal costs related to settlement of the Delhi litigation. Non-cash stock-based compensation expense was $0.76 million (65% of total G&A) and $0.48 million (33% of total G&A) for Q4-09 and Q4-08, respectively. G&A for the quarter ended June 30, 2009, includes the reversal of accrued bonuses of $0.51 million ($16.12 per BOE of production), and a charge of $0.37 million ($11.71 per BOE of production), related to the payment of 2009 bonuses through the issuance of common stock in lieu of cash.

    Fiscal Year Results

    Revenues for FY-09 increased 43% over fiscal year 2008 ("FY-08") to $6.1 million on a 160% increase in production, offset by a 45% decrease in blended oil and gas prices received. Net loss in FY-09 was $2.6 million, or $(0.10) per share, compared to net loss for FY-08 of $1.6 million, or $(0.06) per share. The fiscal year results included non-cash stock-based compensation expense of $2.4 million in 2009 and $1.8 million in 2008.

    For FY-09, Adjusted EBITDA was $1.3 million compared to $0.06 million for the same period in 2008.

    Capital expenditures incurred during the year ended June 30, 2009 were $8.6 million for the acquisition and development of oil and gas properties, with an additional $0.5 million related to recognition of asset retirement obligations.

    Conference Call

    Evolution Petroleum will host a conference call today at 11:00 a.m. Eastern Time (10:00 a.m. Central) to discuss its fiscal fourth quarter 2009 results. To access the call, please dial 480-629-9819 and ask for the Evolution Petroleum call at least 10 minutes prior to the start time. The conference call will also be broadcast live via the Internet and can be accessed through the investor relations section of Evolution's corporate website, http://www.evolutionpetroleum.com/, where it will also be archived for replay. A telephonic replay of the conference call will be available until September 23, 2009 and may be accessed by calling 303-590-3030 and using the pass code 4159937#. For more information, please contact Donna Washburn at DRG&E at (713) 529-6000 or email at dmw@drg-e.com.

    About Evolution Petroleum

    Evolution Petroleum Corporation (http://www.evolutionpetroleum.com/) acquires known, onshore oil and gas resources and applies conventional and specialized technology to accelerate production and develop incremental reserves and value. The Company is well positioned to continue its development projects in CO2 based EOR, bypassed resources and low cost shale gas. Principal assets as of July 1, 2009 include 3.9 MMBOE of proved and probable reserves in the Giddings Field of Central Texas, 0.5 MMBO of proved and unproved reserves with 79 additional locations in South Texas, 13.6 MMBO of probable reserves in the Delhi CO2-EOR project in northeast Louisiana, 17,600 net acres of leases in shallow gas shale in Eastern Oklahoma and our proprietary artificial lift technology.

    Additional information, including the Company's annual report on Form 10-K and its quarterly reports on Form 10-Q, can be accessed on its website.

    Cautionary Statement

    All statements contained in this press release regarding potential results and future plans and objectives of the Company are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update or review any forward-looking statement, whether as a result of new information, future events, or otherwise. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding our ability to complete transactions, successfully apply technology applications in the re-development of oil and gas fields, realize future volumes, realize success in our drilling and development activity, prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward- looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

    Reconciliation of net loss to Adjusted EBITDA, a non-GAAP measure, for the year ended June 30, 2009 and 2008 is as follows: 2009 2008 Net loss $(2,601,593) $(1,570,974) Add back: Income tax benefit (1,016,864) (1,085,454) Depreciation, depletion and amortization 2,461,162 903,214 Stock-based compensation 2,405,900 1,791,486 Accretion on asset retirement obligations 37,601 20,196 Adjusted EBITDA $1,286,206 $58,468 ========== ======= Reconciliation of net (loss) income to Adjusted EBITDA, a non-GAAP measure, for the Q4-09 and Q4-08 is as follows: 2009 2008 Net (loss) income $(709,642) $377,249 Add back: Income tax benefit (420,627) (236,493) Depreciation, depletion and amortization 552,153 530,569 Stock-based compensation 760,365 480,043 Accretion on asset retirement obligations 13,149 3,540 Adjusted EBITDA $195,398 $1,154,908 ======== ========== Company Contact: Sterling McDonald, VP & CFO (713) 935-0122 smcdonald@evolutionpetroleum.com Lisa Elliott / lelliott@drg-e.com Jack Lascar / jlascar@drg-e.com DRG&E / 713-529-6600 - Tables to Follow - Evolution Petroleum Corporation and Subsidiaries Consolidated Statements of Operations (Unaudited) Three Months Ended Year Ended June 30 June 30 ------- ------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues Oil sales $409,546 $1,253,479 $2,747,494 $2,918,127 Natural gas liquids 283,434 558,735 1,625,063 670,434 Natural gas sales 290,971 544,290 1,722,626 667,567 Price risk management activities - - - - --- --- --- --- Total revenues 983,951 2,356,504 6,095,183 4,256,128 ------- --------- --------- --------- Operating Expense: Lease operating expenses 376,969 284,099 1,281,989 1,255,787 Production taxes 21,272 44,021 158,794 90,252 Depreciation, depletion and amortization 552,153 530,569 2,461,162 903,214 Accretion of asset retirement obligation 13,149 3,540 37,601 20,196 General and administrative 1,173,497 1,434,814 5,896,366 5,497,237 --------- --------- --------- --------- Total operating expenses 2,137,040 2,297,043 9,835,912 7,766,686 --------- --------- --------- --------- (Loss) income from operations (1,153,089) 59,461 (3,740,729) (3,510,558) Other income: Interest income 22,820 81,295 122,272 854,130 ------ ------ ------- ------- Net (loss) income before income taxes (1,130,269) 140,756 (3,618,457) (2,656,428) Income tax benefit (420,627) (236,493) (1,016,864) (1,085,454) -------- -------- ---------- ---------- Net loss (709,642) 377,249 (2,601,593) (1,570,974) ======== ======= ========== ========== Earnings per share: Basic and diluted $(0.03) $0.01 $(0.10) $(0.06) Weighted average number of common shares outstanding: Basic and diluted 26,133,023 26,807,214 26,366,677 26,786,270 Evolution Petroleum Corporation and Subsidiaries Consolidated Balance Sheets (Unaudited) June 30, June 30, 2009 2008 ---- ---- Assets Current assets Cash and cash equivalents $3,891,764 $11,272,280 Certificates of deposit 2,059,147 - Receivables Oil and natural gas sales 532,318 2,066,300 Income taxes - 478,599 Other 172,314 86,966 Income taxes recoverable 2,055,802 3,625,987 Prepaid expenses and other current assets 162,441 270,938 ------- ------- Total current assets 8,873,786 17,801,070 --------- ---------- Property and equipment, net of depreciation, depletion, and amortization Oil and natural gas properties - full-cost method of accounting, of which $9,819,465 and $8,754,429 at June 30, 2009 and 2008, respectively, were excluded from amortization. 28,751,178 22,047,233 Other property and equipment 150,697 161,027 ------- ------- Total property and equipment 28,901,875 22,208,260 ---------- ---------- Other assets 53,162 356,518 ------ ------- Total assets $37,828,823 $40,365,848 =========== =========== Liabilities and Stockholders' Equity Current liabilities Accounts payable $690,639 $2,892,459 Accrued payroll 51,318 772,559 Royalties payable 218,477 473,327 Other current liabilities 257,361 32,703 ------- ------ Total current liabilities 1,217,795 4,171,048 Long term liabilities Deferred income taxes 3,721,317 2,901,929 Asset retirement obligations 664,710 215,056 Deferred rent 77,858 74,081 ------ ------ Total liabilities 5,681,680 7,362,114 --------- --------- Commitments and contingencies (Note 12) Stockholders' equity Preferred stock, par value $0.001; 5,000,000 shares authorized; no shares issued or outstanding - - Common stock; par value $0.001; 100,000,000 shares authorized; issued 27,318,517 shares; outstanding 26,530,317 shares and 26,870,439 shares as of June 30, 2009 and 2008, respectively. 27,318 26,870 Additional paid-in capital 16,815,417 14,188,841 Retained earnings 16,186,430 18,788,023 ---------- ---------- 33,029,165 33,003,734 Treasury stock, at cost, 788,200 shares at June 30, 2009. (882,022) - -------- --- Total stockholders' equity 32,147,143 33,003,734 ---------- ---------- Total liabilities and stockholders' equity $37,828,823 $40,365,848 =========== =========== Evolution Petroleum Corporation and Subsidiaries Consolidated Statements of Cash Flow (Unaudited) Year Ended June 30, 2009 2008 ---- ---- Cash flows from operating activities Net loss ($2,601,593) ($1,570,974) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation, depletion and amortization 2,461,162 903,214 Stock-based compensation 2,426,009 1,791,486 Issuance of common stock for charitable donation 28,600 - Accretion of asset retirement obligations 37,601 20,196 Settlement of asset retirement obligations (90,761) - Deferred income taxes 819,388 2,563,928 Deferred rent 3,777 26,792 Other assets 6,236 6,236 Changes in operating assets and liabilities: Receivables from oil and natural gas sales 1,533,982 (1,876,090) Receivables from income taxes and other 1,963,436 (3,747,852) Prepaid expenses and other current assets 108,497 90,902 Accounts payable and accrued expenses (486,706) 468,866 Royalties payable (254,850) 466,496 -------- ------- Net cash provided by (used in) operating activities 5,954,778 (856,800) --------- -------- Cash flows from investing activities Net proceeds from the sale of the Tullos Assets - 4,420,868 Proceeds from other asset sales - 31,582 Development of oil and natural gas properties (8,063,465) (11,187,291) Acquisitions of oil and natural gas properties (2,603,098) (8,789,501) Capital expenditures for other equipment (28,635) (87,544) Purchases of certificates of deposit (1,757,312) - Other assets (4,715) (6,052) ------ ------ Net cash used in investing activities (12,457,225) (15,617,938) ----------- ----------- Cash flows from financing activities Proceeds from issuance of restricted stock 130 76 Purchase of treasury stock (882,022) - Other 3,823 - ----- --- Net cash provided by (used in) financing activities (878,069) 76 -------- --- Net decrease in cash and cash equivalents (7,380,516) (16,474,662) Cash and cash equivalents, beginning of period 11,272,280 27,746,942 ---------- ----------- Cash and cash equivalents, end of period $3,891,764 $11,272,280 ========== =========== Evolution Petroleum Corporation and Subsidiaries Condensed Operating Data (Unaudited) Year Ended June 30 -------- % 2009 2008 Variance change ---- ---- -------- ------ Volumes, net to the Company: Crude oil (Bbl) 36,026 29,466 6,560 22% NGLs (Bbl) 44,125 10,639 33,486 315% Natural gas (Mcf) 323,301 69,051 254,250 368% ------- ------ ------- --- Crude oil, NGLs and natural gas (BOE) 134,035 51,614 82,421 160% Revenue data: Crude oil $2,747,494 $2,918,127 $(170,633) (6)% NGLs 1,625,063 670,434 954,629 142% Natural gas 1,722,626 667,567 1,055,059 158% --------- ------- --------- --- Total revenues $6,095,183 $4,256,128 $1,839,055 43% Average price: Crude oil (per Bbl) $76.26 $99.03 $(22.77) (23)% NGLs (per Bbl) 36.83 63.02 (26.19) (42)% Natural gas (per Mcf) 5.33 9.67 (4.34) (45)% ---- ---- ----- --- Crude oil, NGLs and natural gas (per BOE) $45.47 $82.46 $(36.99) (45)% Expenses (per BOE) Lease operating expenses and production taxes $10.69 $25.39 $(14.70) (58)% Depletion expense on oil and natural gas properties $18.07 $16.44 $1.63 10%

    Evolution Petroleum Corporation

    CONTACT: Sterling McDonald, VP & CFO of Evolution Petroleum Corporation,
    +1-713-935-0122, smcdonald@evolutionpetroleum.com; or Lisa Elliott,
    lelliott@drg-e.com, or Jack Lascar, jlascar@drg-e.com, both of DRG&E,
    +1-713-529-6600, for Evolution Petroleum Corporation

    Web Site: http://www.evolutionpetroleum.com/




    Newpark Resources Announces Third Quarter 2009 Earnings Release and Conference Call Schedule

    THE WOODLANDS, Texas, Sept. 16 /PRNewswire-FirstCall/ -- Newpark Resources, Inc. announced today that it will release its third quarter 2009 results on Thursday, October 29, 2009 after the market closes. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the Internet, for Friday, October 30, 2009 at 10:00 a.m. Eastern / 9:00 a.m. Central.

    What: Newpark Resources Third Quarter 2009 Earnings Conference Call When: Friday, October 30, 2009 at 10:00 a.m. Eastern / 9:00 a.m. Central How: Live via phone -- By dialing 480-629-9770 and asking for the Newpark Resources call at least 10 minutes prior to the start time, or Live over the Internet - By logging onto the web at the address below Where: http://www.newpark.com/

    For those who cannot listen to the live call, a replay will be available through November 6, 2009 and may be accessed by dialing (303) 590-3030 and using pass code 4160781#. Also, an archive of the webcast will be available shortly after the call at http://www.newpark.com/ for 90 days.

    Newpark Resources, Inc. is a worldwide provider of drilling fluids, temporary worksites and access roads for oilfield and other commercial markets, and environmental waste treatment solutions. For more information, visit our website at http://www.newpark.com/.

    Contacts: James E. Braun, CFO Newpark Resources, Inc. 281-362-6800 Ken Dennard, Managing Partner Dennard Rupp Gray & Easterly, LLC ksdennard@drg-e.com 713-529-6600

    Newpark Resources, Inc.

    CONTACT: James E. Braun, CFO of Newpark Resources, Inc.,
    +1-281-362-6800; or Ken Dennard, Managing Partner of Dennard Rupp Gray &
    Easterly, LLC, +1-713-529-6600, ksdennard@drg-e.com, for Newpark Resources,
    Inc.

    Web Site: http://www.newpark.com/




    Polaris Software Launches Intellect GUB CBX at Sibos

    CHENNAI, India, September 16 /PRNewswire-FirstCall/ -- - ...Three of the World's Largest Global Transaction Banks Showcase Solutions Powered by Intellect CBX

    Polaris Software Lab Limited (POLS.BO), a leading Financial Technology Company today launched Intellect GUB 10.0, the most comprehensive corporate banking solution at Sibos 2009. Intellect GUB 10.0 offers functionality and technology architecture to create Customer Business eXchange (CBX) that can significantly enhance banking experience of corporate customers.

    Intellect Global Universal Banking (GUB) 10.0 is a unique banking platform that offers most comprehensive products across the wholesale banking spectrum from trade finance, cash management, treasury, commercial lending, commercial cards, securities services and payments with built-in shared business services such as collateral management, limit monitoring, payment governance, analytics layer and a powerful unified portal. The solution harnesses the power of SOA to modernize bank's technology platform and enables bank to rapidly launch new products for its emerging lines of business.

    Customer Business eXchange enables transaction services and information exchange for all or a 'mix and match' combination of Intellect GUB 10.0 functionality that is uniquely required by corporate banks. Banks can utilize CBX for corporate customers and provide them with a single entry into the complete suite or mix of corporate products and services such as Liquidity management, Treasury, Trade, Custody and Payments.

    Intellect GUB 10.0 and CBX are being showcased to the leading corporate bankers from around the world participating in Sibos 2009, the world's premier financial services event being hosted in Hong Kong.

    Launching Intellect GUB 10.0, Mr. Arun Jain, Chairman & CEO, Polaris Software Lab Ltd., said, "Corporate Banking community is looking at innovative and collaborative ways to create new growth models. The comprehensive and agile technology architecture of Intellect GUB 10.0 enables banks to create CBX that offers the ability to transact across departmental solutions thereby improving sales & operational productivity and customer retention. With its unique proposition of constructing tailor made solutions, I am delighted to find CBX getting phenomenal acceptance at Sibos."

    Commenting on the launch, Mr. Kartik Kaushik, President - Global Sales and Account Management, said, "Intellect GUB offers unmatched interoperability and the ease of bringing together comprehensive and functionally rich components in the form of CBX. We have been able to deliver customized and innovative corporate banking solutions with fastest time to market using our approach of CBX. At Sibos, three of the world's largest global transaction banks are showcasing solutions powered by Intellect CBX."

    About Polaris Software Lab

    Polaris Software Lab (POLS.BO) is a leading Financial Technology company, with its comprehensive portfolio of products, services and consulting. Polaris has a talent strength of over 9,000 solution architects, domain and technology experts. The company owns the largest set of Intellectual Properties in the form of a comprehensive product suite, Intellect Global Universal Banking (GUB) 10.0. IntellectTM is the first pure play SOA based application suite for Retail, Corporate and Investment banking.

    Polaris is headquartered in Chennai and has offices in all global financial hubs including Tokyo, Sydney, Hong Kong, Singapore, India, Dubai, Bahrain, Riyadh, London, Belfast, Zurich, Frankfurt, Toronto, New York, Chicago, Fremont, Pittsburgh and Chile. For more information, please visit http://www.polaris.co.in/

    For more information, please contact: Shailesh Dhawla Polaris Software Lab Tel: +91-99620-23124 Email: shailesh.d@polaris.co.in

    Polaris Software Lab Limited

    CONTACT: For more information, please contact: Shailesh Dhawla, Polaris
    Software Lab, Tel: +91-99620-23124, Email: shailesh.d@polaris.co.in




    Charge Into Fall with Fresh Updates for the HomeLighting, Textures and Colors Change the Look

    RICHMOND, Va., Sept. 16 /PRNewswire/ -- The following article is cleared for use, in whole or part, with attribution to designer Kristi Pipes Lane. Optional by-line credit is Jody LoMenzo.

    Fall means a shift from outdoor living to indoors; and for many, those same four walls can become increasingly boring. How about a quick fix to freshen rooms and charge into fall? Richmond-based Interior designer Kristi Pipes Lane with architecture/design firm 3north offers up some easy and inexpensive tips to update your home and improve your living space. With saving money on everyone's mind, plan on some affordable do-it-yourself improvements to make your home your haven.

    1. Replace outdated lighting fixtures. Lane says, "Look for more decorative lighting like pendant fixtures and wall sconces. These are the inexpensive and easy to update, adding new focus and drama. Use pendants in kitchens, centered over islands or seating groups; in bathrooms, they're great!" Lane is thumbs down on fluorescent tube lighting. "Change any fixture that requires 24" tubes. They are just awful!"

    2. Change the rug, change the room. "Try a sea grass rug," Lane suggests. "Their neutral tones go with any decor, and they are affordable, especially if you can work with a standard size. Try Pottery Barn, Crate and Barrel or West Elm for these easy-to-clean floor coverings." Lane believes that a good amount of flooring border should show. "Always allow for the floor to show all the way around the room. I think 18" is the minimum border. I always try for 24." And layering a smaller, more expensive rug over the sea grass is the best way to get the most bang for your buck. Use the small rug centered under your seating grouping.

    3. New hardware can change the look and feel of cabinets and drawers. "The after-effect from this change is amazing," Lane notes. She loves Restoration Hardware for their large variety and styles. "Remember to check the width of your pulls -- they come in standard sizes like 4", 6" -- so you use the existing holes. With knobs, watch the diameter. Too big or too small can ruin the look." Lane also recommends updating furniture with new pulls and knobs, "You'll think you have a new piece and it's a dramatic change for under $50.00!"

    4. Slipcovers offer more than one look for upholstered pieces. "Slipcovers not only allow you to make a quick change, but they help protect your upholstery," says Lane. The designer likes covers and pieces by Coveralls, part of Lee Industries. "Their covers are even reversible for more flexibility. Their website is full of good options." http://www.leeindustries.com/.

    5. Paint it; change it. "Paint is the cheapest, fastest way to change a room and you can do it yourself," says Lane. "I love Farrow & Ball paints. Their colors are unique and rich. They are a national line with stores in major cities and can be ordered on the web." http://www.farrow-ball.com/

    Lane's forecast for Fall 2009, "Color will be very dramatic. Use lots of black accents. Purple is still big, but people either love it or hate it. You can't go wrong with turquoise and aqua blues. These colors seem to be more timeless and always work well with neutrals. Dark marine blue is making a comeback. This shade works for both modern and traditional -- male environs and more feminine settings. This deep shade -- not your old tired navy, but a richer green-hued blue, works well with gold and silver accents. It makes a great room for blondes," notes the blonde-haired Lane.

    If you have questions, would like to interview Lane or request a headshot, please contact Jody LoMenzo at Point of View Public Relations, povpr@comcast.net or 804-272-1031. More info on Lane is available at http://www.3north.com/

    Kristi Pipes Lane

    CONTACT: Jody LoMenzo at Point of View Public Relations,
    +1-804-272-1031, povpr@comcast.net

    Web Site: http://www.3north.com/




    The re3 Concept: Triple Symbiosis Between Form, Function and Finesse

    BURSCHEID, Germany, September 16 /PRNewswire/ --

    - Johnson Controls Presents New Concept Car at IAA 2009

    Picture is available via EPA (European Pressphoto Agency) and can be downloaded free of charge at: http://www.presseportal.de/pm/19526/johnson_controls_gmbh/?keygroup=bild

    Well thought out from three perspectives and implemented in its entirety: Johnson Controls' re3 concept car brings together extraordinary demands on state-of-the-art vehicle interiors in the compact class segment. At IAA 2009, one of the world's leading suppliers of automotive interior systems, electronics and batteries presents solutions for the future that are all possible right now. In the re3 concept, Johnson Controls displays a product package that is not limited to a single vehicle and satisfies current market demands: reduced weight, easy-to-follow arrangement of systems and modules in the vehicle interior, greater use of modular technology and design flexibility. The focus is on sustainability, with the goal of reducing fuel consumption and emissions while increasing comfort and safety at the same time.

    The re3 concept car is showcased with a light, pure, yet simultaneously comfortable and generously spacious vehicle interior containing extraordinary display and control concepts and innovative seating solutions. The use of sustainable materials and unique design approaches ensures a harmonious, personal ambience. The re3 is powered by a powerful, environmentally friendly lithium-ion high energy battery. The name re3 stands for "rethink, renew and respond" and is the development formula adopted by Johnson Controls' engineers and designers, who have raised their skills to new levels in this new concept car. "The result is a symbiosis between innovative product ideas and process technologies, sustainable material use and the comprehensive implementation of contemporary design concepts," said Detlef Jürss, Vice President Engineering Seating, Interiors and Systems Europe, Africa and South America.

    EcoSpace cockpit structure allows for space and greater freedom of design EcoSpace is a hybrid cockpit structure using plastic and steel that eliminates half of the traditional cross-car beam. The steel is used on the driver's side in the form of a tripod, while the plastic is used across the full cockpit width. Air channels and the connection to the airbag are incorporated directly into the plastic structure, enabling the automakers to benefit from a weight reduction of up to 26 percent compared to conventional cross-car beams. For the vehicle designers, the use of the EcoSpace concept constitutes a major plus in terms of freedom of design. For instance, they now have total flexibility in designing the space in front of the passenger. Besides reducing weight, optimizing available construction space was a key focus in the development of the re3 cockpit structure. The goal was to remove as many functions as possible from the cockpit and locate them in more appropriate positions from a functional perspective. As a result, and considering that there are many other conceivable layout options, Johnson Controls was able to create more leg room for the front seat passenger while also creating very spacious storage compartments. As a result, the glove compartment was thus 150 percent larger. To achieve variety of design and give the vehicle interior a stylish appeal, the instrument panel and door panels were made from the same environmentally friendly and visible natural fiber material, giving the surfaces a natural appearance.

    A futuristic layout and at the same time suitable for day-to-day use In the re3 concept car, the electronic control functions and user interfaces that were previously located in the center/tunnel console or the door panels were removed and integrated into an alternative, ergonomically favorable position. The electronic controls, parts of the user interfaces for the infotainment system and all of the controls for the HVAC (heating, ventilation and air conditioning) functions and other control and comfort functions have now been conveniently integrated into the driver's right armrest. All of this was intended to achieve a new spatial and design concept.

    Efficient lithium-ion high-energy battery offers sustainability The expertise of the world leader in the automobile battery segment comes to the forefront in the re3 concept with the integration of a lithium-ion high-energy battery for the plug-in hybrid concept. It is far more powerful than the traditional nickel metal hydride batteries that are still used in most hybrid vehicles. The highly efficient, liquid-cooled battery contains 7.6 kWh of energy and is available for series production. You can drive about 50 km with this battery in pure electric battery mode before the internal combustion engine kicks in - making it about ten times more powerful than the batteries in current use. In theory, you could drive to work in electric mode, charge it while there, and then drive back again on fully electric power. In this connection, Johnson Controls has positioned the battery in the tunnel console between the two front seats for maximum safety.

    Slim executive seats optimize passenger communication In the re3 concept, Johnson Controls has used the super-slim "Slim Seat", which offers the front passenger a high level of seating comfort while leaving a generous amount of knee room for the passenger in the back. This is achieved by using a conventional backrest structure with a thin layer of seat foam and also Comfort Shell technology, which individually adapts to the passenger's body shape. These seats with the characteristic slim profile are made entirely using a modular structure (MS) in the seat base and back area. To reduce the risk of whiplash in a vehicle collision, the seats have been fitted with a crash-active head restraint that propels forward in the event of a collision.

    The developers also focused intensively on the question of how to break through the traditional communication barrier between front and rear-seat passengers so as to encourage conversation between the seat rows. The result was the "Conversational Seating" concept. Added value for all passengers is provided by the seating arrangement, which creates a conversational triangle by means of a front passenger seat that slides backward into the second row using an extended track, together with fold-away rear seats and a mechatronic release mechanism. The new seating position not only gives the front passenger a unique amount of leg room, but also proves highly practical for interaction with a rear-seat passenger, for instance to attend to a child more easily.

    With the re3 concept, Johnson Controls has created a vehicle that is simultaneously intelligent and functional while offering additional space as well as environmentally friendly and inconspicuously stylish. "Our new concept car can hold its own in today's difficult market conditions, because it points in innovative directions in the compact class segment with a range of accessories and optional equipment that trigger the impulse to purchase, are sought by consumers and are a way for our customers to differentiate themselves from the competition," said Detlef Jürss.

    A more technically detailed version of the press release and digital photos are available at http://www.johnsoncontrols.co.uk/press.

    Johnson Controls (NYSE: JCI) is the global leader that brings ingenuity to the places where people live, work and travel. By integrating technologies, products and services, we create smart environments that redefine the relationships between people and their surroundings. Our team of 140,000 employees creates a more comfortable, safe and sustainable world through our products and services for more than 200 million vehicles, 12 million homes and one million commercial buildings. Our commitment to sustainability drives our environmental stewardship, good corporate citizenship in our workplaces and communities, and the products and services we provide to customers. For additional information, please visit http://www.johnsoncontrols.com.

    Further information is available from: Johnson Controls GmbH Automotive Experience Industriestr. 20-30 51399 Burscheid Germany Astrid Schafmeister Tel.: +49-2174-65-3189 Fax: +49-2174-65-3219 E-mail: astrid.schafmeister@jci.com Ina Longwitz Tel.: +49-2174-65-4343 E-mail: ina.longwitz@jci.com

    Johnson Controls GmbH

    Further information is available from: Johnson Controls GmbH, Automotive Experience, Industriestr. 20-30, 51399 Burscheid, Germany; Astrid Schafmeister, Tel.: +49-2174-65-3189, Fax: +49-2174-65-3219, E-mail: astrid.schafmeister@jci.com; Ina Longwitz, Tel.: +49-2174-65-4343, E-mail: ina.longwitz@jci.com




    Aricent and Cavium Networks Collaborate to Provide LTE Evolved Packet Core SolutionsJoint effort combines Aricent EPC frameworks and Cavium's OCTEON-II Multi-core MIPS64 Processor family yielding highly-scalable, optimized solutions for LTE Equipment Manufacturers

    PALO ALTO, Calif., Sept. 16 /PRNewswire/ -- Aricent(TM), a global innovation, technology and services company focused exclusively on communications, today announced a Long Term Evolution (LTE) Evolved Packet Core (EPC) development collaboration with Cavium Networks , a leading provider of semiconductor products that enable intelligent processing for networking, wireless, storage and video applications. Through this collaboration, the companies will offer pre-optimized, performance-enhanced and highly-scalable EPC Serving Gateway (SGW), PDN Gateway (PGW) and Mobility Management Entity (MME) ready-to-use software frameworks for Cavium's OCTEON(TM) Multi-core MIPS64 processor family. This joint effort creates significant technology synergies, offering LTE equipment manufacturers a high-performance, high-capacity solution for their EPC platforms, while simultaneously reducing time to market, risk and cost.

    Aricent's LTE EPC software framework is based upon the company's mature and widely deployed DIAMETER and GTP product stacks. The frameworks are complete, pre-integrated control plane software modules suitable for LTE Macro/Micro EPC nodes, supporting essential SGW, PGW and MME capabilities. Aricent's frameworks integrate the complete control plane (signaling) functionality of the EPC node into a seamless package, accelerating and simplifying development of highly scalable, carrier-class EPC solutions. Aricent's LTE EPC framework will be available and pre-optimized on the current Cavium OCTEON Plus Processor family and the upcoming OCTEON II Processor family. To learn more about Aricent's LTE technology, please go to http://info.aricent.com/lte1.html.

    "Aricent has a successful track record providing mobile communications technology and services to the world's leading infrastructure manufacturers," said YJ Kim, senior director, networking and communications division at Cavium Networks. "Combining Aricent's LTE expertise and software technology with OCTEON Multi-core MIPS64 processors will provide our mutual customers with an optimized, robust and reliable solution for EPC applications. Together, Aricent and Cavium will reduce OEM development time and engineering cost for all Macro and Mini EPC node types. Building upon our existing eNodeB solution, we now offer a complete range of LTE network elements for our joint customers."

    The OCTEON Processor Family is the industry's broadest Multi-core MIPS64 based Processor Family with over 30 different integrated processors with application performance ranging from 1Gbps to 40+Gbps. The OCTEON Processor Family consists of processors with 1 to 32 cores on a single chip with integrated multiple GEs, 10GEs, sRIO, PCI-express or PCI-X networking interfaces with industry-leading hardware acceleration for packet processing, quality of service, TCP, IPsec, KASUMI, SNOW 3G, ROHC, compression / decompression and deep packet inspection.

    "Cavium Networks' OCTEON Processor Family has won numerous designs at tier-1 3.5G and LTE infrastructure vendors. Our collaboration with Cavium reflects our continued emphasis on alignment with technology leaders in the LTE space," said Rakesh Vij, assistant vice president at Aricent. "In addition to our device, eNodeB, IP backhaul and access software, Aricent has created a complete integrated framework for LTE EPC nodes. Cavium's semiconductor expertise combined with our software frameworks simplifies development complexity for LTE infrastructure customers."

    Aricent and Cavium will be showcasing their respective LTE solutions at 4G World in Chicago. September 16-17, 2009. Aricent in will be exhibiting in booth # 811 and Cavium at Booth # 833.

    Aricent is a trusted Cavium development partner and a proud member of Cavium's Partnership to Accelerate Customer End-solutions (PACE) program. For more information regarding Cavium's extensive network of world class partners please visit http://www.caviumnetworks.com/Ecosystem_Partners.php

    Keywords & tags: EPC, Evolved Packet Core, SGW, PGW, MME, Packet Data Network Gateway, Serving Gateway, LTE, LTE Frameworks, Cavium, OCTEON Processor, OCTEON II, OCTEON CN5860, CN5650, CN63XX, PACE, eGTP, GTPv2, LTE Diameter, LTE GTP, MME NAS, LTE Reference Designs

    About Aricent

    Aricent is a global innovation, technology and services company focused exclusively on communications. Aricent combines the leading innovation capabilities of frog design with unparalleled domain expertise in communications as a strategic supplier to the world's foremost infrastructure, application and service providers. The company's investors include Kohlberg Kravis Roberts & Co., Sequoia Capital, The Family Office and Flextronics International Ltd. For more information, visit http://www.aricent.com/

    About Cavium Networks

    Cavium Networks is a leading provider of highly integrated semiconductor products that enable intelligent processing in networking, wireless, storage and video applications. Cavium Networks offers a broad portfolio of integrated, software compatible processors ranging in performance from 10 Mbps to 40 Gbps that enable secure, intelligent functionality in enterprise, data-center, broadband/consumer and access & service provider equipment. Cavium Networks processors are supported by ecosystem partners that provide operating systems, tool support, reference designs and other services. Cavium Networks principal offices are in Mountain View, CA with design team locations in California, Massachusetts, India and Taiwan. For more information, please visit: http://www.caviumnetworks.com/

    Aricent is a trademark of Aricent Inc. in the United States and other jurisdictions. All other trademarks are the property of their respective owners.

    Aricent

    CONTACT: Angel Atondo of Cavium Networks, +1-650-623-7033,
    angel.atondo@caviumnetworks.com; or Steven Manuel of Aricent, +1-650-391-1621,
    steven.manuel@aricent.com; or Chris Lalli of Cohn & Wolfe, +1-415-365-8540,
    chris.lalli@cohnwolfe.com, for Aricent Americas; or Paula Muezerie of AxiCom,
    +44 208 392 4081, aricent@axicom.com, for Aricent Europe; or Shikha Singh
    Sehrawat of Text 100, +91 989 107 1999, shikhas@text100.co.in, for Aricent
    India

    Web Site: http://www.aricent.com/
    http://www.caviumnetworks.com/




    Forterus Inc. Launches Updated, Improved Web Site

    MURRIETA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Forterus Inc. (Pink Sheets: FTER), which, through its ABTTC Inc. division provides drug and alcohol rehabilitation and a variety of other behavioral healthcare services with the highest levels of accreditation, announced today that it has updated its web sites at http://www.forterushealthcare.com/ and http://www.abttc.com/, its "A Better Tomorrow" facility.

    "It is very important that visitors to our web sites understand our treatment philosophies, our successes and the resources we have available," said Paul Howarth, co-founder and CEO. "Our improved web site gives those seeking treatment, and shareholders and potential investors, a much clearer picture of Forterus Inc., our strengths and beliefs."

    The new web site also includes testimonials, frequently asked questions, such as insurance issues, a virtual tour of the facilities, significant information about rehabilitation and the opportunity for live chat, background about the staff, a mission and vision statement, plus news about the Company.

    "Movie stars are known to spend tens of thousands or more, but our goal at 'A Better Tomorrow' is to offer services which are fair and reasonable. In many ways, this can be the best decision of one's life, and we don't want to see anyone miss that opportunity because of finances," Mr. Howarth said.

    CONTACT: Paul Howarth, CEO 888/257-8345 ir@forterushealthcare.com Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com

    Forterus Inc.

    CONTACT: Paul Howarth, CEO of Forterus Inc., 1-888-257-8345,
    ir@forterushealthcare.com; or Paul Knopick of E & E Communications,
    +1-949-707-5365, pknopick@eandecommunications.com, for Forterus Inc.

    Web Site: http://www.forterushealthcare.com/
    http://www.abttc.com/




    Autonomy Applies its Advanced Meaning-based Technology to Transform Database MarketAdvanced Probabilistic Technology Developed by Autonomy for Unstructured Information Now Brings Intelligence to Structured Data

    CAMBRIDGE, England and SAN FRANCISCO, September 16 /PRNewswire-FirstCall/ -- Autonomy Corporation plc , a global leader in infrastructure software for the enterprise, today announced IDOL Structured Probabilistic Engine (SPE), a new product that applies Autonomy's meaning-based technology to databases to deliver a new level of intelligence to this $18 billion market. Autonomy built its business on pioneering the market for understanding unstructured data, and today over 20,000 customers depend on Autonomy technology for a range of business applications. Now Autonomy is applying the same advanced technologies to transform the database market, by turning legacy RDBMSs into next-generation probabilistic inference engines that can understand "shades of gray".

    Corporations are dependent on RDBMS technology to power literally every type of business software application. While databases perform operations, the software doesn't understand the meaning of the data itself and is limited to viewing the world as black or white. With the use of advanced probabilistic methodologies, Autonomy delivers new levels of database processing intelligence, enabling the software to suggest results, even when an exact match doesn't exist in the database. This technology represents a radical shift in the intelligence businesses can gain from information, by delivering the ability to understand the "meaning" in the data in the billions of corporate databases in use today.

    A self-learning solution, IDOL SPE can automatically make connections in the data that would otherwise need to be interpreted by human beings. The solution analyzes interactions, usage, and multiple datasets to spot patterns in structured data and make non-obvious predictions. Unlike business intelligence solutions that require building and maintaining complex cubes that operate outside the database, IDOL SPE brings probabilistic inference into existing databases.

    For instance, an airline can leverage IDOL SPE to improve the online customer experience and increase sales. A customer searching for a flight from New York to San Francisco at a date and time when all flights are sold out will automatically be offered an alternative airport such as Oakland or San Jose, rather than returning "no results" to the customer's search. IDOL SPE infers the result from patterns in the data and its usage without the need for scripts or geographic information.

    "Autonomy was built on one fundamental technology, IDOL, that brought meaning to human friendly information," said Mike Lynch, CEO of Autonomy. "IDOL SPE is our second fundamental technology and ushers the database market into the era of meaning-based computing. Organizations are now able to free data from rigid structures to deliver relevance and understanding that can impact literally every type of computing application."

    Autonomy's IDOL SPE is available now in limited release as a standalone product or as an add-on accelerator to existing database applications.

    Please visit http://www.autonomy.com/freeyourdata to find out more. About Autonomy

    Autonomy Corporation plc , a global leader in infrastructure software for the enterprise, spearheads the meaning-based computing movement. It was recently ranked by IDC as the clear leader in enterprise search revenues, with market share nearly double that of its nearest competitor. Autonomy's technology allows computers to harness the full richness of human information, forming a conceptual and contextual understanding of any piece of electronic data, including unstructured information, such as text, email, web pages, voice, or video. Autonomy's software powers the full spectrum of mission-critical enterprise applications including pan-enterprise search, customer interaction solutions, information governance, end-to-end eDiscovery, records management, archiving, business process management, web content management, web optimization, rich media management and video and audio analysis.

    Autonomy's customer base is comprised of more than 20,000 global companies, law firms and federal agencies including: AOL, BAE Systems, BBC, Bloomberg, Boeing, Citigroup, Coca Cola, Daimler AG, Deutsche Bank, DLA Piper, Ericsson, FedEx, Ford, GlaxoSmithKline, Lloyds TSB, NASA, Nestle, the New York Stock Exchange, Reuters, Shell, Tesco, T-Mobile, the U.S. Department of Energy, the U.S. Department of Homeland Security and the U.S. Securities and Exchange Commission. More than 400 companies OEM Autonomy technology, including Symantec, Citrix, HP, Novell, Oracle, Sybase and TIBCO. The company has offices worldwide. Please visit http://www.autonomy.com/ to find out more.

    Autonomy and the Autonomy logo are registered trademarks or trademarks of Autonomy Corporation plc. All other trademarks are the property of their respective owners.

    Autonomy Editorial Contacts: Randy Cairns Autonomy (US) +1-408-953-7111 randy.cairns@autonomy.com Ian Bain The Red Consultancy (US) +1-415-618-8806 ian.bain@redconsultancy.com Edward Bridges Financial Dynamics (UK) +44-207-831-3113 edward.bridges@fd.com David Vindel The Red Consultancy (UK) +44-207-025-6529 david.vindel@redconsultancy.com

    Autonomy Corporation plc

    CONTACT: Autonomy Editorial Contacts: Randy Cairns, Autonomy (US) ,
    +1-408-953-7111, randy.cairns@autonomy.com; Ian Bain, The Red Consultancy
    (US), +1-415-618-8806, ian.bain@redconsultancy.com; Edward Bridges,
    Financial Dynamics (UK), +44-207-831-3113, edward.bridges@fd.com; David
    Vindel, The Red Consultancy (UK), +44-207-025-6529,
    david.vindel@redconsultancy.com




    Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan

    GENEVA, September 16 /PRNewswire/ -- Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Easypod(R) was developed for exclusive use with cartridges of Saizen(R) (somatropin), Merck Serono's human recombinant growth hormone for the treatment of growth hormone deficiency.

    Easypod(R) is an innovative electronic auto injection device designed to improve ease of usage, reliability and convenience for patients who need daily subcutaneous injections of Saizen(R). It allows patients to self-inject in just three simple key steps. Additionally, a built-in dose memory automatically records the number of doses administered, allowing physicians and caregivers to accurately monitor patient adherence to therapy.

    "Easypod is both an easy to use and intelligent device enabling physicians to track patients' adherence to Saizen therapy, which is an essential component for optimal treatment outcomes," said Franck Latrille, Executive Vice President, Head of Commercial International at Merck Serono. "We are pleased to offer this innovative and successful device today to patients in Japan."

    Easypod(R) is registered in 39 other countries worldwide including European countries and the United States. In Japan, easypod(R) will be launched in September 2009.

    About Growth Hormone Deficiency

    Growth hormone (GH) plays a central role in the growth process and maturation from child- to adulthood and regulates a number of metabolic and physiologic processes during the whole life. In children lack of GH will result in delayed maturation and short stature, whilst in adults the signs are more subtle, and include several psychological features, such as depression, anxiety, poor memory, and social isolation, as well as the physiological problems of weakness, poor vitality, easy fatigue, and weight gain. The current prevalence of pediatric GH disorder is estimated globally to be 100,000 children[1] and in Europe 50,000 adults suffer from the condition[2].

    1 Journal of Clinical Endocrinology and Metabolism 1997;V.82 No.2:349

    2 GH and IGF Research 2001; 11: 137-165

    About Saizen(R)

    Saizen(R) (somatropin) is a recombinant human growth hormone (GH) and is therapeutically equivalent to the natural GH produced by the body.

    Saizen(R) is currently registered in 78 countries for the treatment of: - GH deficiency in children - GH deficiency in adult patients - Children born Small for Gestational Age - Turner's syndrome - GH deficiency in children associated with chronic renal failure

    The registered indications vary slightly from one country to another.

    About Merck Serono

    Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

    Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R) and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R), bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in all markets.

    With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

    About Merck

    Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 33,000 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

    For more information, please visit http://www.merckserono.com or http://www.merck.de

    http://www.merckserono.com

    Merck Serono S A

    Merck Serono, 9 Chemin des Mines Media Relations, 1202 Geneva Tel.: +41-22-414-36-00, Switzerland




    Epson PowerLite Pro Cinema 9100 Wins CustomRetailer 2009 EXC!TE AwardHigh-Performing 1080p Projector Offers Custom Installers Tailored Big Screen Home Theater Solution

    LONG BEACH, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Adding to Epson's home entertainment projector accolades, the new PowerLite Pro Cinema 9100 has been honored as a 2009 CustomRetailer Magazine EXC!TE Award winner. The EXC!TE Awards recognize products that stand out for being innovative, high-performing and solutions-oriented for the custom installation professional.

    The new Pro Cinema 9100 delivers a high-quality big screen experience at home. This native 1080p resolution 3LCD(TM) home theater projector features a high contrast of 36,000:1 and brightness of 1,800 lumens color and white light output(1), as well as enhanced color reproduction for outstanding image quality and more natural and precise colors. With ISF calibration and color isolation, the Pro Cinema 9100 offers a customized home entertainment experience to accommodate a range of installation options.

    "We are delighted with the acknowledgement received from CustomRetailer for the new Pro Cinema 9100," said Marge Ang, senior product manager, Epson America. "The award and recognition underscores Epson's commitment to delivering custom installers high-quality, high-performing home entertainment solutions."

    The Pro Cinema 9100 offers home theater enthusiasts high-definition 3LCD image quality and home entertainment performance, delivering bright and natural color, crisp image detail, and reliability. Housed in a stylish black and silver design, the Pro Cinema 9100 features an exclusive Dynamic Iris system which contributes to higher contrast and controls light on a frame-by-frame basis at up to 60 times per second, making it ideal for fast-action movies.

    The EXC!TE Awards are presented annually by CustomRetailer, the leading business strategy publication for custom installers, integrators and custom retailers for various new, cutting-edge products, ventures, and technology. Winners are chosen by the publication's editorial staff. The 2009 award winners were formally announced on Sept. 10 at CEDIA EXPO out of a field of over 450 entries.

    Availability and Support

    Available in October, the Pro Cinema 9100 can be purchased through authorized Epson projector dealers and select retail outlets and comes with Epson's industry leading service and support, including a three-year limited warranty with toll-free access to Epson's PrivateLine(SM) priority technical support, 90-day limited lamp warranty, and free two-business day exchange with Extra Care(SM) Home Service. For more details on the Pro Cinema 9100 please visit http://www.epson.com/newsroom.com.

    About Epson America Inc.

    Epson America Inc. is the U.S. affiliate of Japan-based Seiko Epson Corporation (SEC) and is a leading provider of digital imaging products that exceed the vision of its customers. The company's extensive range of printers, 3LCD projectors and small- and medium-sized LCDs are renowned for their superior quality, functionality, compactness, and energy efficiency. The Seiko-Epson organization is proud of its ongoing contributions to the global environment and was recently added to the Dow Jones Sustainability World Index, an indicator for leading companies in economic, environmental and social criteria.

    Note: Epson is a registered trademark of Seiko Epson Corporation. PowerLite is a registered trademark of Epson America Inc. All other product and brand names are trademarks and/or registered trademarks of their respective companies. Epson disclaims any and all rights in these marks.

    (1) Light output varies depending on modes (color and white light output). White light output measured using ISO 21118 standard.

    Epson America Inc.

    CONTACT: Duane Brozek of Epson America Inc., +1-562-290-5683,
    duane_brozek@ea.epson.com; or Sara Lee of Walt & Company, +1-408-369-7200,
    ext. 2980, slee@walt.com

    Web Site: http://www.epson.com/




    easypod(R), dispositif d'injection de l'hormone de croissance de Merck Serono, approuvé au Japon

    GENEVE, Suisse, September 16 /PRNewswire/ -- Merck Serono, division de Merck KGaA (Darmstadt, Allemagne), annonce aujourd'hui que l'agence japonaise en charge des dispositifs médicaux, la "Pharmaceutical and Medical Devices Agency (PMDA)", a accordé une autorisation de mise sur le marché pour easypod(R) au Japon. Easypod(R) a été développé pour une utilisation exclusive avec les cartouches de Saizen(R) (somatropine), l'hormone de croissance humaine recombinante de Merck Serono, indiqué pour le traitement des déficits en hormone de croissance.

    Easypod(R) est un dispositif électronique d'auto-injection innovant, conçu pour améliorer la facilité, la fiabilité et la commodité d'utilisation chez les patients ayant recours à des injections sous-cutanées quotidiennes de Saizen(R). Ce dispositif permet aux patients de s'administrer eux-mêmes leur traitement en trois étapes-clés simples. De plus, une mémoire intégrée enregistre automatiquement le nombre de doses administrées, ce qui permet aux médecins et aux personnels soignants de suivre précisément l'observance du traitement par le patient.

    "Easypod(R) est un dispositif médical facile d'utilisation, mais intelligent aussi puisqu'il permet aux médecins de contrôler l'adhésion de leurs patients au traitement par Saizen(R), ce qui constitue un facteur essentiel pour la réussite optimale du traitement," a déclaré Franck Latrille, Vice Président Exécutif Commercialisation Internationale de Merck Serono. "Nous sommes heureux de pouvoir mettre à la disposition des patients japonais cet auto-injecteur innovant qui a déjà rencontré un grand succès auprès des patients."

    easpyod(R) est autorisé dans 39 autres pays dans le monde, dont en Europe et aux Etats-Unis. Le lancement d' easypod(R) au Japon est prévu en septembre 2009.

    À propos des déficits en hormone de croissance

    L'hormone de croissance joue un rôle essentiel dans la croissance et la maturation, depuis l'enfance jusqu'à l'âge adulte, et régule, durant toute la vie, plusieurs processus physiologiques et métaboliques. Chez l'enfant, le déficit en hormone de croissance est à l'origine d'un retard de croissance et d'une petite taille, alors que chez l'adulte, les manifestations sont plus subtiles et comprennent diverses manifestations psychologiques telles que dépression, anxiété, troubles mnésiques et isolement social, ainsi que des troubles physiologiques caractérisés par une faiblesse musculaire, un manque de dynamisme, une fatigabilité et une prise de poids. La prévalence actuelle des déficits en hormone de croissance est estimée chez l'enfant à 1/100 000[1] dans le monde et, chez l'adulte, à 1/50 000[2] en Europe.

    [1] Journal of Clinical Endocrinology and Metabolism 1997;V.82 No.2:349

    [2] GH and IGF Research 2001; 11: 137-165

    À propos de Saizen(R)

    Saizen(R) (somatropine) est une hormone de croissance humaine recombinante, équivalente sur le plan thérapeutique à l'hormone de croissance naturelle secrétée par l'organisme. Saizen(R) est enregistré actuellement dans 78 pays pour le traitement :

    - du déficit en hormone de croissance de l'enfant,

    - du déficit en hormone de croissance de l'adulte,

    - des enfants nés avec une petite taille pour leur âge gestationnel,

    - du syndrome de Turner,

    - du déficit en hormone de croissance chez l'enfant insuffisant rénal chronique.

    Les indications homologuées varient légèrement d'un pays à un autre.

    À propos de Merck Serono

    Merck Serono est la division spécialisée dans les médicaments de prescription innovants de Merck KGaA, compagnie pharmaceutique et chimique basée à Darmstadt (Allemagne) et opérant à l'échelle mondiale. Merck Serono, dont le siège est à Genève (Suisse), découvre, développe, produit et commercialise des médicaments innovants visant à aider des patients dont les besoins médicaux sont insatisfaits. Merck Serono dispose d'une expertise à la fois pour les médicaments obtenus par synthèse chimique et pour ceux issus de la biotechnologie. Aux États-Unis et au Canada, EMD Serono opère par le biais de filiales juridiquement indépendantes.

    Merck Serono met à la disposition des patients des médicaments phares dans les domaines de l'oncologie (Erbitux(R), cetuximab), de la sclérose en plaques (Rebif(R), interféron bêta-1a), de l'infertilité (Gonal-f(R), follitropine alpha), des troubles endocriniens et métaboliques (Saizen(R) et Serostim(R), somatropine), (Kuvan(R), dichlorhydrate de saproptérine), ainsi que les maladies cardiométaboliques (Glucophage(R), metformine), (Concor(R), bisoprolol), (Euthyrox(R), lévothyroxine). Ces médicaments ne sont pas tous disponibles sur tous les marchés.

    Avec un budget annuel d'environ un milliard d'euros consacré à la Recherche & Développement, Merck Serono a pour objectif de poursuivre la croissance de ses activités dans des domaines thérapeutiques spécialisés, dont les maladies neurodégénératives, l'oncologie, la fertilité et l'endocrinologie, ainsi que dans de nouveaux domaines thérapeutiques tels que les maladies auto-immunes et inflammatoires.

    À propos de Merck

    Merck est un groupe pharmaceutique et chimique mondial, dont les ventes se sont élevées à 7,6 milliards d'euros en 2008. Fort d'une histoire qui a commencé en 1668, Merck construit son avenir grâce à ses 33 800 employés répartis dans 60 pays. Sa réussite tient au sens de l'innovation de ses employés. Les activités de Merck sont chapeautées par la société Merck KGaA, dont le capital est détenu à hauteur d'environ 70% par la famille Merck et à hauteur d'environ 30% par des actionnaires extérieurs. La filiale américaine Merck & Co. a été expropriée en 1917, et n'a depuis plus aucun lien avec le groupe Merck Serono.

    Pour obtenir des informations complémentaires, veuillez consulter les sites http://www.merckserono.net ou http://www.merck.de

    http://www.merckserono.com

    Merck Serono S A

    Merck Serono, 9 Chemin des Mines Media Relations, 1202 Geneva Tel.: +41-22-414-36-00, Switzerland




    18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard ChemotherapyUpdate Also Demonstrates 3.3-month Improvement over Standard Chemotherapy in Median Overall Survival

    SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

    The table below shows the primary end of treatment data analyses previously reported and the new updated 18 month efficacy data analyses. This data is part of CTI's presentation today at the BioCentury NewsMakers conference at 10:30 AM ET.

    End of Treatment 18 Month Follow-Up ---------------- ------------------ CR/CRu CR/CRu ---------------- ------------------ Pixantrone 20.0% 25.7% Control 5.7% 7.1% P Value 0.021 0.005 ORR ORR ---------------- ------------------ Pixantrone 37.1% 40.0% Control 14.3% 14.3% P Value 0.003 0.001 End of Treatment 18 Month Follow-Up ---------------- ------------------ Progression Free Progression Free Survival Survival ---------------- ------------------ Pixantrone 4.7 months 5.6 months Control 2.6 months 2.6 months P Value 0.007 (HR = 0.60) 0.002 (HR = 0.56) Median Overall Median Overall Survival Survival ---------------- ------------------ Pixantrone 8.1 months 10.2 months Control 6.9 months 6.9 months P Value 0.54 (HR = 0.88) 0.3 (HR = 0.82)

    "We continue to be impressed by the durability of responses in the pixantrone treatment arm which seemed to improve during the study follow up period, compared to the standard chemotherapy recipients - whose responses and duration of response are largely unchanged from the initial assessment period," noted James A. Bianco, M.D., Chief Executive Officer of CTI. "We are also encouraged by the increase in the overall survival estimates, especially among those patients whose histologic diagnosis was verified by independent pathologists where 40% of pixantrone recipients were alive, compared to 27% for standard chemotherapy at the 1 year landmark period. We plan to submit these updated safety and efficacy data to our NDA as part of the 120 Day update."

    The FDA typically receives updated clinical study data 120 days following the initial NDA submission.

    The most common (incidence greater than or equal to 20%) adverse reactions reported for pixantrone-treated subjects were neutropenia, infection, anemia, leucopenia, thrombocytopenia, asthenia, pyrexia, and cough.

    Pixantrone has been accepted for standard review by the Food & Drug Administration (FDA), with fast track status with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

    BioCentury's NewsMakers in the Biotech Industry Conference CTI Presentation: Wednesday, September 16, 2009 10:30 a.m. Eastern /7:30 a.m. Pacific /6:30 p.m. Central European Audio webcast with slides at http://www.celltherapeutics.com/ About the EXTEND (PIX301) Clinical Trial

    The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed or refractory, aggressive nonHodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission (CR) or unconfirmed complete remission (uCR) rate, time to tumor progression, and overall survival. The study was conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) and pixantrone has received fast track designation for this indication.

    About Pixantrone

    Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status designation.

    About Cell Therapeutics, Inc.

    Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

    Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_alert

    This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (including the failure to achieve the overall response rate, complete remissions and progression-free survival and the possibility of significant grade 3, 4 adverse effects, including cardiac disorders) for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA, that CTI does not submit the 18-month follow-up data to the FDA as part of the 120-day update, and the possibility that the follow-up data does not demonstrate continued improvement in the primary and secondary endpoints, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: deramian@ctiseattle.com http://www.celltherapeutics.com/press_room Investors Contact: Ed Bell T: 206.282.7100 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: invest@ctiseattle.com http://www.celltherapeutics.com/investors Medical Information Contact: T: 800.715.0944 E: info@askarm.com

    Cell Therapeutics, Inc.

    CONTACT: Media, Dan Eramian, +1-206-272-4343, cell: +1-206-854-1200,
    deramian@ctiseattle.com, or Investors, Ed Bell, +1-206-282-7100, or Lindsey
    Jesch Logan, +1-206-272-4347, fax: +1-206-272-4434, invest@ctiseattle.com, all
    of Cell Therapeutics, Inc.; or Medical Information, 1-800-715-0944,
    info@askarm.com

    Web Site: http://www.celltherapeutics.com/




    Cell Therapeutics, Inc.'s (CTI) Presentation at BioCentury NewsMakers Conference to be Webcast

    SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at BioCentury's NewsMakers in the Biotech Industry conference on Wednesday, September 16, 2009, at 10:30 AM Eastern.

    The conference will be held September 16, 2009, at the Millennium Broadway Hotel in New York.

    The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at http://www.celltherapeutics.com/.

    BioCentury's NewsMakers in the Biotech Industry Conference CTI Presentation: Wednesday, September 16, 2009 10:30 a.m. Eastern /7:30 a.m. Pacific /6:30 p.m. Central European Audio webcast with slides at http://www.celltherapeutics.com/ Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 F: 206.272.4434 E: media@ctiseattle.com http://www.celltherapeutics.com/press_room Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: invest@ctiseattle.com http://www.celltherapeutics.com/investors

    Cell Therapeutics, Inc.

    CONTACT: Media, Dan Eramian , +1-206-272-4343, cell, +1-206-854-1200,
    fax, +1-206-272-4434, media@ctiseattle.com, or Investors, Ed Bell,
    +1-206-272-4345, or Lindsey Jesch Logan, +1-206-272-4347 , fax,
    +1-206-272-4434 , invest@ctiseattle.com, both of Cell Therapeutics, Inc.

    Web Site: http://www.celltherapeutics.com/




    GENova Biotherapeutics forming academic partnerships

    New York, Sept. 15 /PRNewswire-FirstCall/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it is forming strategic alliances with academic research institutions specializing in ground-breaking stem cell research.

    Forming relationships with academia gives GENova a strategic advantage in its business of identifying and acquiring promising early-stage biotechnologies for treatment of oncological and infectious diseases. The company already has solid relationships in place with a number of leading universities, as well as with research labs, hospitals, biotechnology companies, and contract research organizations around the globe. It hopes to bolster its list of alliances in the coming weeks and months.

    "By forming strategic partnerships with leading-edge academic institutions, we gain the inside track to accessing exciting new drug targets way ahead of the competition," says CEO for GENova Aaron Whiteman. "These relationships are key to maintaining the strength of our acquisition pipeline of potential blockbuster biotechnologies."

    Early-stage partnerships with academic institutions underpin GENova's business strategy of acquiring, developing, and then out-liscencing promising new drug targets to major pharmaceutical companies. GENova is capitalizing on an important trend among pharmaceutical companies wherein almost half of their revenues are now generated from in-licensing early-stage products from companies like GENova. The market for effective cancer therapeutics is immense, with revenues projected to rise to US$60.6 billion by 2011.

    About GENova Biotherapeutics Inc.

    GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: http://www.genovabio.com/.

    Forward Looking Statements

    This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

    GENova Biotherapeutics, Inc.

    CONTACT: Investor Relations: Brian Cook, Windfall Communications LLC,
    1-866-797-8703, info@windfallcommunications.com




    Prepare for an All-Out Assault With Xbox 360 Modern Warfare 2(R) Limited Edition ConsoleMicrosoft and Activision unveil an exclusive global console based on Infinity Ward's 'Modern Warfare 2' with 250GB Hard Drive, more storage space than ever before

    SANTA MONICA, Calif. and REDMOND, Wash., Sept. 15 /PRNewswire-FirstCall/ -- Microsoft Corp. and Activision Publishing, Inc. today brandished the latest weapon to help gamers take to the battlefields for the global launch of the year with the announcement of the Xbox 360 Modern Warfare 2 Limited Edition Console. Infinity Ward's "Modern Warfare 2," the blockbuster sequel to the best-selling first-person action game in history, "Call of Duty 4: Modern Warfare ," was the inspiration for the console's high-speed, low-drag, battle-ready design, which is available for pre-order today at U.S. retailers and in other regions later this week.

    (Photo: http://www.newscom.com/cgi-bin/prnh/20090915/LA76491)

    Beginning with "Call of Duty: Modern Warfare 2's" worldwide release on Nov. 10, fans can arm themselves with Xbox 360 Modern Warfare 2 Limited Edition Console, which features an exclusive design inspired by the epic thriller, more storage space than ever before in a 250GB Hard Drive, two Xbox 360 Wireless Controllers, as well as an Xbox 360 Headset and a Standard Edition copy of "Modern Warfare 2" for an estimated retail price of $399.99 (USD).

    "It's the highest compliment to the team and our fans to have a special themed Xbox 360 console," said Vince Zampella, CEO of Infinity Ward. "The precision and detail that's been put into the console captures the intensity and feel of 'Modern Warfare 2.' We can't wait for our community and fans around the world to see for themselves on Nov. 10."

    The Xbox 360 Modern Warfare 2 Limited Edition Console was revealed at an exclusive preview event in Los Angeles where guests were the first to experience "Modern Warfare 2" multiplayer gameplay on Xbox LIVE.

    "It is thrilling to bring the exclusive 'Modern Warfare 2'-inspired Xbox 360 console to Call of Duty fans. Being able to work so closely with the talented team at Infinity Ward on the design has enabled us to develop a console that will set bragging rights around the world," said Albert Penello, senior director of global marketing for Xbox 360. "These fans deserve the biggest Xbox 360 console ever, and we're delivering with more storage space than ever before and freedom to enjoy their favorite games and downloadable Game Add-ons, including the first two 'Modern Warfare 2' maps that will be available first on Xbox LIVE."*

    Xbox 360 Modern Warfare 2 Limited Edition Console, will be sold in Europe, the Middle East (UAE, Saudi Arabia), UK, U.S., Canada, Mexico, Colombia, Chile, Australia and New Zealand.

    On Nov. 10, Activision Publishing, Inc. will release Infinity Ward's "Call of Duty: Modern Warfare 2." The title continues the gripping and heart-racing action as players face off against a new threat dedicated to bringing the world to the brink of collapse. "Modern Warfare 2" is rated "M" (Mature - Blood, Drug Reference, Intense Violence and Language) by the ESRB. For more information, visit http://www.modernwafare2.com/ or http://www.xbox.com/en-US/games/c/callofdutymodernwarfare2/.

    About Xbox 360

    Xbox 360 is a premier video game and entertainment system. It is home to the best and broadest games as well as the largest on-demand library of standard- and high-definition movies and TV shows connected to the television -- with music coming this fall. The digital center of the living room, Xbox 360 blends unbeatable content with the largest online social network connected to the television in the 20 million members on Xbox LIVE to create a limitless entertainment experience that can be shared at home or across the globe. With the addition of currently code-named "Project Natal," Xbox 360 will forever transform social gaming and entertainment with a whole new way to play -- no controller required. More information about "Project Natal" and Xbox 360 can be found online at http://www.xbox.com/projectnatal and http://www.xbox.com/.

    About Xbox LIVE

    Xbox LIVE is the largest gaming and entertainment network and delivers more entertainment than any device connected to the television, including movies, TV and games, with music coming this fall. This fall, Xbox LIVE will be the only entertainment service to provide instant-on 1080p streaming HD video from Zune video in supported countries. With an active community of more than 20 million people across 26 countries, Xbox LIVE lets you play the best games, enjoy the largest on-demand library and, coming soon, listen to millions of songs -- all while connecting to friends anytime. An Xbox LIVE Gold Membership provides you with exclusive benefits and premium access to entertainment from the top studios and services, all in one place. More information about Xbox LIVE can be found online at http://www.xbox.com/live.

    About Microsoft

    Founded in 1975, Microsoft (Nasdaq "MSFT") is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

    About Activision Publishing, Inc.

    Headquartered in Santa Monica, California, Activision Publishing, Inc. is a leading worldwide developer, publisher and distributor of interactive entertainment and leisure products.

    Activision Publishing maintains operations in the U.S., Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, Norway, Denmark, the Netherlands, Australia, Russia, Japan, South Korea, China and the region of Taiwan. More information about Activision and its products can be found on the company's website, http://www.activision.com/.

    * Add-ons sold separately.

    Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Activision Publishing generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming" and similar expressions to identify forward-looking statements. Factors that could cause Activision Publishing's actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include, but are not limited to, sales levels of Activision Publishing's titles, shifts in consumer spending trends, the impact of the current macroeconomic environment, the seasonal and cyclical nature of the interactive game market, Activision Publishing's ability to predict consumer preferences among competing hardware platforms (including next-generation hardware), declines in software pricing, product returns and price protection, product delays, retail acceptance of Activision Publishing's products, adoption rate and availability of new hardware and related software, industry competition, rapid changes in technology and industry standards, protection of proprietary rights, litigation against Activision Publishing, maintenance of relationships with key personnel, customers, vendors, licensees, licensors and third-party developers, counterparty risks relating to customers, licensees, licensors and manufacturers, domestic and international economic, financial and political conditions and policies, foreign exchange rates, integration of recent acquisitions and the identification of suitable future acquisition opportunities, Activision Blizzard's success in completing the integration of the operations of Activision Publishing and Vivendi Games in a timely manner, or at all, and the combined company's ability to realize the anticipated benefits and synergies of the transaction to the extent, or in the timeframe, anticipated, and the other factors identified in the risk factors section of Activision Blizzard's most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to Activision Publishing and Activision Blizzard as of the date of this release, and neither Activision Publishing nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Activision Publishing or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

    2009 Activision Publishing, Inc. Activision, Call of Duty and Modern Warfare are registered trademarks of Activision Publishing, Inc. All rights reserved. All other trademarks and trade names are the properties of their respective owners.

    Photo: http://www.newscom.com/cgi-bin/prnh/20090915/LA76491
    PRN Photo Desk, photodesk@prnewswire.com Activision Publishing

    CONTACT: Jessica Lange, +1-323-202-1419, jessica.lange@edelman.com, or
    Tina Yu, +1-206-268-2248, tina.yu@edelman.com, both of Edelman, for Xbox 360;
    or John Rafacz, +1-310-496-5207, john.rafacz@activision.com, or Josh Selinger,
    +1-310-496-5287, joshua.selinger@activision.com, both of Activision
    Publishing, Inc.

    Web Site: http://www.activision.com/

    Company News On-Call: http://www.prnewswire.com/comp/007396.html




    Federal Court Sides With Industry Icon Karl W. Miller, Dismissing With Prejudice All Claims of Wrongdoing Alleged Against Him by MMC Energy, Inc.

    MIAMI, Sept. 15 /PRNewswire/ -- Karl W. Miller today announced that the pending Federal suit brought by MMC Energy, Inc. against him, its founder and former Chairman and CEO, was dismissed almost in its entirety by the Federal Court in its September 14, 2009 decision. The Court granted Mr. Miller's motion to dismiss the Company's suit against him on all claims except for breach of contract.

    The Federal Court ordered that all of the Company's claims of wrongdoing by Mr. Miller (i.e. fraud and tortuous interference with advantageous business relations) be dismissed with PREJUDICE, indicating that the Company failed to substantiate these false claims with any evidence whatsoever, and was only "vaguely" able to allege injuries sustained.

    The Court's decision held that the Company failed to demonstrate that Mr. Miller made any misrepresentations or omissions with respect to any duty he owed to the Company after leaving. The Court also denied the Company's motion seeking a default judgment against Mr. Miller.

    As to the remaining allegation of breach of contract, Mr. Miller, a well respected energy industry pioneer and icon, will vigorously defend himself against this claim and the evidence will demonstrate that this claim too is without merit.

    Mr. Miller has filed a Federal action against the Company and its Directors in the United States District Court for the Southern District of Florida for damages in excess of $5,000,000 in addition to substantial punitive damages.

    The Federal action filed by Mr. Miller alleges that George Rountree III, the lead independent director of the Company and Chairman of the compensation committee, Sylvia Rountree and Richard Bryan, Chairman of the governance committee, and Chairman and CEO Michael J. Hamilton for fraud, extortion, defamation and their intentional infliction of severe emotional distress.

    The company announced that shareholders voted on September 14, 2009 to approve the complete dissolution and liquidation of the company and its assets. The Board of Directors and management of the Company have claimed in SEC filings it is the only alternative to bankruptcy under their stewardship.

    George Rountree III and his wife Sylvia Rountree reside in Wilmington, North Carolina. George Rountree III is a partner at the law firm Rountree, Losee and Baldwin. Sylvia Rountree is a member of the Board of Trustees at the New Hanover Regional Medical Center in Wilmington, North Carolina.

    George Rountree, who is a practicing lawyer in Wilmington, North Carolina and is also a member of the board of directors at Southern Union Company, will receive total compensation of at least $334,000.00 when MMC ceases to exist. The Rountrees' holdings are subject to review by the Securities and Exchange Commission ("SEC").

    About Mr. Miller:

    Mr. Miller is a globally recognized energy executive and institutional investor with a balance of both financial and energy sector expertise. Mr. Miller began his career on Wall Street during the 1980's and has an extensive background in banking, commodities trading and risk management.

    Mr. Miller has a long history in the global energy business and has held a variety of executive management positions both within the United States, Europe and Asia. Mr. Miller has bid on over $25 billion in energy related assets during his career.

    Mr. Miller has built, restructured and managed energy businesses for major public energy companies on several continents, including PG&E Corporation, Electricity de France, El Paso Energy, Enron Corporation and JPMorgan Chase.

    Mr. Miller holds an MBA in Finance from the Kennan-Flagler Business School at The University of North Carolina, Chapel Hill. Mr. Miller also holds a B.A. in Accounting from Catholic University located in Washington DC.

    Mr. Miller is currently on medical leave until late 2009.

    VBCC

    CONTACT: Steven Kaiser, Esq., +1-212-239-9669, for VBCC




    Harry Winston Diamond Corporation announces Diavik Diamond Mine cancels winter production shutdown

    TORONTO, Sept. 15 /PRNewswire-FirstCall/ -- Harry Winston Diamond Corporation (TSX: HW, NYSE: HWD) is pleased to announce Diavik Diamond Mines Inc.'s decision to cancel a winter production shutdown at the Diavik mine in Canada's Northwest Territories.

    Earlier this year, Diavik had announced a series of actions in response to changes in market conditions, including plans for a summer and winter production shutdown. The summer shutdown was safely and successfully concluded on August 24 and rough diamond production has returned to pre shutdown levels. The winter shutdown, which has now been cancelled, was originally planned for 1 December 2009 through 11 January 2010.

    Robert Gannicott, Chairman and Chief Executive Officer of Harry Winston Diamond Corporation commented "We are pleased to be able to resume regular supplies of Diavik diamonds to our valued customer base who, in turn, appreciate continuity of supply in support of their own businesses. We do not foresee a return to extreme conditions that would warrant a further shutdown"

    During the summer production shutdown Diavik remained in compliance with all permits and licences. Mining and processing of ore ceased but other work, including environmental monitoring, raising of the embankment around the processed kimberlite containment area, and planned equipment maintenance occurred. Approximately 600 workers were affected but were able to use accumulated leave entitlements or access salary averaging.

    The Diavik Diamond Mine, currently an open pit mine, is planning to commence underground production in early 2010. By 2012, Diavik expects open pit mining will cease at which time Diavik will become an all underground mine.

    About Harry Winston Diamond Corporation

    Harry Winston Diamond Corporation is a specialist diamond enterprise with assets in the mining and retail segments of the diamond industry. Harry Winston supplies rough diamonds to the global market from its 40 percent ownership interest in the Diavik Diamond Mine (economic ownership of 31%).

    The Company's retail division is a premier diamond jeweler and luxury timepiece retailer with salons in key locations, including New York, Paris, London, Beijing, Tokyo, and Beverly Hills.

    The Company focuses on the two most profitable segments of the diamond industry, mining and retail, in which its expertise creates shareholder value. This unique business model provides key competitive advantages; rough diamond sales and polished diamond purchases provide market intelligence that enhances the Company's overall performance.

    For investor information, visit http://investor.harrywinston.com/ or call Investor Relations on (416) 362-2237 ext 290

    Harry Winston Diamond Corporation

    CONTACT: please visit http://www.harrywinston.com/




    Fannie Mae annonce les résultats des enchères de la réouverture des obligations Benchmark Notes(R) échéant dans 5 ans

    WASHINGTON, September 16 /PRNewswire/ --

    Le présent communiqué est émis par Fannie Mae (NYSE : FNM) :

    5 ans (réouverture) Date de fixation du prix 15 septembre 2009 Date de règlement 17 septembre 2009 Date d'échéance 16 septembre 2014 Valeur à la réouverture 1 G $US En circulation 3 G $US Coupon 3,000% Prix 101,221 Rendement 2,737 % Dates de paiement Tous les 16 septembre et 16 mars à partir du 16 septembre 2009 CUSIP 31398AYY2 Inscription Les inscriptions de titres seront faites sur le marché EuroMTF de la Bourse de Luxembourg

    Fannie Mae est une société détenue par des actionnaires qui a une mission de nature publique. Notre raison d'être est d'augmenter le nombre de logements à prix abordable et de fournir des capitaux mondiaux aux communautés locales afin de servir le marché américain du logement. Fannie Mae a une charte fédérale et évolue sur le marché hypothécaire secondaire américain pour accroître les liquidités du marché hypothécaire en fournissant des fonds aux instituts de crédit foncier et aux autres prêteurs de façon à ce qu'ils puissent effectuer des prêts aux acquéreurs de logement. Notre travail consiste à aider ceux qui habitent l'Amérique.

    Le présent communiqué ne constitue pas une offre de vente ni la sollicitation d'une offre d'achat des titres de Fannie Mae. Il ne contient aucun conseil concernant les avantages de l'achat ou de la vente d'un investissement particulier. Toute décision d'investissement relative à l'achat des titres mentionnés aux présentes doit être prise uniquement en fonction des renseignements contenus dans la Note d'information applicable de Fannie Mae, et du fait qu'il ne faut pas tenir pour acquis que les renseignements contenus dans le présent communiqué sont exacts ou exhaustifs.

    La négociation des titres suppose une connaissance de leur nature et de l'étendue des risques encourus. Vous devez vous assurer que les titres choisis conviennent à vos ressources et à votre situation financière. En cas de doute, vous devriez consulter un conseiller financier compétent en la matière.

    Benchmark Notes est une marque déposée de Fannie Mae. L'utilisation non autorisée de cette marque est interdite.

    Fannie Mae

    Latressa Cox, +1-202-752-6707, ou Centre des ressources : +1-800-732-6643




    Microsoft and M-Com Deliver Mobile Payments Solution Globally

    HONG KONG, September 16 /PRNewswire/ --

    - Leading mobile banking software vendor leverages the Microsoft platform to deliver the most flexible and scalable mobile payments solution.

    Microsoft Corp. and M-Com today announced a solution offering that provides banks and payment processors with industry-leading mobile payments functionality - creating more opportunities for banks to offer mobile payments services to their customers and maximize their revenue opportunities. This solution clearly demonstrates that consumer choice and deployment flexibility for banks are key to the success of global mobile payments solutions for the financial services industry. The announcement was made at Sibos 2009, the industry's premier global financial services forum.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

    Using Microsoft technologies, M-Com BankAnywhere provides a complete end-to-end mobile payments solution for the banking industry worldwide. The comprehensive solution provides best-practice security and risk management capabilities, ensuring that banks can effectively manage the exposure of their brands and services in the emerging market for mobile technology. As a fully integrated solution, it reduces the total cost of ownership (TCO) for the mobile channel for banks.

    A Microsoft Gold Certified Solution Developer, M-Com supports BankAnywhere across the globe and, in doing so, utilizes Microsoft resources and best practices in deploying BankAnywhere. The use of standard Microsoft technology, including Windows and Microsoft SQL Server, as well as Internet Information Services (IIS), allows enterprise users of BankAnywhere to benefit from existing industry-standard technology management tools and practices.

    "Consumers today have many options and channels, requiring financial services firms to engage customers through a highly personalized, connected experience - consistent across all touch points - that builds strong relationships, creates customer intimacy and boosts loyalty," said Susan Hauser, vice president of Worldwide Financial Services at Microsoft. "Today's announcement underscores our efforts to provide multichannel integration that allows financial institutions to benefit from mobile and new media channels as part of the overall connected experience. Our alliance with M-Com expands our partner ecosystem for payments and mobile solutions and further validates our leadership position as a provider of payment processing platforms."

    Financial institutions, facing declining revenue from traditional credit cards, are looking to use mobile payments to replace cash-dominated lower value payments to generate new revenue streams. This is important for banks and retailers, as cash handling is both expensive and a security risk.

    "With the increasing adoption of mobile applications running on smartphones, the mobile channel can no longer be ignored by banks," said Red Gillen, senior analyst at Celent. "Mobile payments continue to be at the top of the list of applications that will entrench mobile financial services in consumers' daily lives, propelling it into the mainstream. As banks look to invest in this strategic area, vendors that can provide solutions which go beyond simple mobile banking informational services to address other value-added services such as bill payment will be the ones that come out on top."

    For most financial institutions, paper-based payment transactions are expensive to support and offer few opportunities for differentiation. While the cost metrics associated with processing checks and cash payments vary substantively across jurisdictions, financial institutions, and payment types, it is well understood that electronic payments - including those carried out through mobile phones - have a direct positive impact on for the cost structures of payers, payees and financial institutions alike.

    Global consumer demand also is helping to propel this migration. The growing ubiquity of mobile phones and their increasing multifunction capabilities make these devices a compelling candidate for replacing a physical wallet.

    "It is clear that consumers in Asia and around the world have an insatiable demand for mobile financial services, especially payment transactions," said Adam Clark, CEO of M-Com. "Banks must engage their customers and prospects in the mobile channel in the short term to ensure they profit from sustainable revenues and key customer segments that are adopting these services."

    As prominent examples, Bangkok Bank and KeyBank both recently selected a mobile financial services solution that leverages the M-Com BankAnywhere platform. The institutions chose Mobile Money from Fiserv Inc., which was launched in conjunction with M-Com in September 2008. Fiserv, a partner of Microsoft and M-Com, is the leading global provider of financial services technology solutions.

    "The uptake of this cutting-edge consumer banking technology demonstrates a significant shift in how banks across the world connect with their customer," said Karen Campbell, executive vice president at Bangkok Bank. "Customers in Asia are at least as demanding as their counterparts in Europe and the U.S. - they need the portable banking tools to complement their busy, highly mobile lifestyles."

    The mobile payment experience should be delivered across multiple mobile devices, manufacturers and cellular phone carriers to accommodate the personal preferences of the target audience: the consumer. This is the only way that choice can be extended across global markets. BankAnywhere on the Microsoft platform addresses these business imperatives by delivering the following:

    - New revenue opportunities from payment and value-added transactions - Cost elimination through a proven ability to move customers to lower-cost, self-service channels - Differentiation and control over the bank's mobile channel and the user experience they provide to customers

    "We needed a product that would scale to a large number of users and could be extended to meet the diverse needs of Key's multiple lines of business and client segments," said Allison Landers, senior vice president, Virtual Banking, KeyBank. "Mobile banking is a strategic opportunity area for banks. By adopting the M-Com BankAnywhere platform for SMS, we're providing our clients a strong first step into mobile banking with a seamless and compelling user experience."

    Mobile banking services are the best way to open up a mobile-centric relationship with consumers. Open loop payment mechanisms, choice of payment execution models, and interoperability across devices are essential to delivering the optimal experience. With its ecosystem of payments partners, including M-Com and Fiserv, Microsoft is helping banks through the complexity and challenges of mobile financial services.

    About Microsoft in Financial Services

    Microsoft's Financial Services Group provides software that helps financial firms transform the customer, employee and operations experience so they can maximize opportunities for increased market share and profitability. Microsoft software helps empower people and IT staff within financial firms - and across key focus areas such as advisor platforms, channel renewal, insurance value chain, enterprise risk management and compliance, and payments. Through a combination of Microsoft- and partner-provided solutions, customers enable their employees to turn data into insight, transform ideas into action and turn change into opportunity.

    More information about Microsoft's Financial Services Group can be found at http://www.microsoft.com/financialservices.

    About M-Com

    Headquartered in Atlanta, GA, M-Com is an international mobile banking and payments solution provider working with banks and transaction processors in North America, Australasia, Europe, the Middle East and Asia. M-Com's core proposition is centered on delivering world class adoption and revenue metrics from mobile payment services.

    For more information, visit http://www.mcom.co.nz.

    About Microsoft

    Founded in 1975, Microsoft (Nasdaq: MSFT) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

    Microsoft Corp.

    Serge van Dam of M-Com, +1-678-369-0602, serge.vandam@mcom.co.nz; or Wendy Grover of Microsoft Corp., +1-425-705-7609; or Chanda Gathani of Metia, +44-795-11-63615, chanda.gathani@metia.com, for Microsoft Corp.; NOTE TO EDITORS: If you are interested in viewing additional information on Microsoft, please visit the Microsoft Web page at http://www.microsoft.com/presspass on Microsoft's corporate information pages. Web links, telephone numbers and titles were correct at time of publication, but may since have changed. For additional assistance, journalists and analysts may contact Microsoft's Rapid Response Team or other appropriate contacts listed at http://www.microsoft.com/presspass/contactpr.mspx; Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO




    CBp Carbon Industries Announces Pre-Commercial Production for Its First Commercial Plant in Cyprus

    BRATISLAVA, Slovakia, September 16 /PRNewswire/ --

    CBp EU Headquarters - CBp Carbon Industries, Inc. ("CBp" or "the Company") (OTC: CBPJ) is pleased to provide shareholders with an update in its affairs, particularly its progress of plant construction and technology development.

    We are pleased to advise that CBp has reached an exciting milestone in its history by completing the world's largest state-of-the-art operational tire pyrolysis plant. We are proud to advise that our new completed first generation commercial plant in Cyprus is in pre-production and receiving tipping fee revenues. The new plant is just finishing 'hot tests' (processing scrap tires) and will enter continuous commercial operations in Q4. Our plant will commence commercial deliveries of product in Q4, starting with steel and oil deliveries first, with our Carbon Green (our substitute carbon black patented product) reaching full output in Q1 2010 when we have completed our pelletizing process for Carbon Green delivery.

    We are very pleased with the capabilities and dedication of our development team, headed by Peter Tsantrizos who became our Chief Technology Officer and COO early in 2008 when our then CTO, Mr. Jack Fader, suffered serious health problems. Mr. Fader was unable to assist in the Cyprus plant development and this was accomplished entirely by our team under the leadership of Mr. Tsantrizos. However, Mr. Fader was able to continue to provide some technical advice for a period of time in the area of new patent filings and completing transfer of all patents for the technology to our company in 2008/early 2009. Accordingly all patents in respect to our technology including pyrolysis, Carbon Green production and Carbon Green applications belong wholly to CBp.

    Our team overcame all challenges in building the Cyprus plant and have substantially improved our technology with installation of a new horizontal reactor, improved flow processes and improved plant design and configuration. As examples of the skills of our team instead of sub-contracting out installation of major equipment, as initially planned, our team managed the completion of the reactor installation and the fulfilling of electronic and computer control systems themselves thereby developing these areas of expertise within our Company team. Our team's meetings with our main customer, Triputra Group, in Indonesia, to coordinate our production of Carbon Green with their quality requirements (we signed a 200,000 tonne per year 'take or pay' contract for Carbon Green with them) resulted in a decision that we would not master-batch in Cyprus but would pelletize our Carbon Green. This saved us 2 million Euros for masterbatching facilities in Cyprus and will substantially drop our processing costs. However as no one had developed a pelletizing process for our type of product, our team rose to the task and developed a customized pelletizing process for our product. The prognosis for our Cyprus plant, and our new plants being planned, has also greatly increased with the EU's recent requirement that all tires contain a minimum 5% recycled material. This significantly enhances the value of our technology which has been chosen by the EU as the only qualifying/best available technology to meet EU strict tire recycling standards. The result is that our customers are more anxious than ever for access to our products and this seems to insulate our product prices from the recent swings in commodity prices and therefore has created stronger demand.

    Although we have now built two plants (one pilot and one commercial), we are effecting due diligence on a third site, have effected substantial research, conducted extensive development of products and opportunities and borne all the other costs of a major world-wide corporate endeavor, we still have substantial cash left in our treasury and no debt even though we have done little new finance in approximately two years. The Company has now commenced seeking to list the company on a more senior US exchange to better reflect its advanced stage of development.

    John Novak stated "We are extremely pleased with the capabilities of our development team and their ability to deliver on the Company's rapid growth plans. We are confident that we will make a difference in creating value for our stock holders and contributing materially to making this a greener and more sustainable world."

    John Novak

    On Behalf of the Board of Directors and the Company

    About CBp Carbon Industries, Inc.

    CBp Carbon Industries, Inc. is a global company that develops and commercializes our advanced technologies that enrich the environment, the countries and communities in which we operate, and our shareholders. Our primary focus is tire recycling with our patented technology which permits 100% recycling of tires and scrap rubber into commercially viable marketable components of steel, oil and CBp Carbon Green(TM), which is a tested substitute for replacement of carbon black in tire and rubber manufacturing.

    Since 2006, European Union directives have banned scrap tires, shredded tires and tire residues from being landfilled and stockpiled. An EU scientific team, working with the European Union Cooperative Research Recycle Tire (CRAFT) project, selected CBp Carbon Industries technology as the "best available technology" for meeting CRAFT's recycling objectives.

    For more information, please contact: info@cpbcarbon.com

    Web address: www.cbpcarbon.com

    FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding CBp Carbon Industries, Inc. and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where CBp Carbon Industries Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. CBp Carbon Industries Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    CBp Carbon Industries, Inc.

    CBp Carbon Industries, Inc., + 1-778-996-6400, info@cpbcarbon.com




    Vista Gold Corp. Announces Pricing of Common Stock Offering

    DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Vista Gold Corp ("Vista" or the "Company") (TSX & NYSE Amex: VGZ) is pleased to announce the pricing of its previously announced public offering of common stock pursuant to the Company's shelf registration statement filed with the U.S. Securities and Exchange Commission (the "SEC") and a shelf prospectus filed with certain Canadian securities regulatory authorities. The Company has agreed to increase the number of shares sold by 10 percent to 8.8 million shares at a price of US$2.25 per share of common stock. The Company has granted the underwriters a 30-day option to purchase up to 1.32 million additional shares of common stock to cover over-allotments, if any.

    Proceeds to the Company from the offering, net of commissions and expenses, are expected to be approximately US$17.6 million (assuming the underwriters' over-allotment option is not exercised). The offering is expected to close on September 21, 2009.

    Vista intends to use the net proceeds from this offering (i) to fund drilling, exploration, and technical/engineering activities (including the preparation of a feasibility study) on its Mt. Todd gold project, (ii) to fund the engineering, design and other technical activities to advance its Paredones Amarillos gold project, (iii) to fund exploration activities and if warranted, drilling programs at its Guadalupe de los Reyes gold project and (iv) to fund acquisitions, and further development of acquired mineral properties, working capital requirements and/or for other general corporate purposes.

    Dahlman Rose & Company, LLC and Wellington West Capital Markets Inc. are acting as joint book-runners for the offering.

    The offering is being made by way of a registration statement, which has been declared effective by the SEC, a base shelf prospectus and a final prospectus supplement each of which has been filed with the SEC and each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Newfoundland and Labrador. A copy of the final prospectus supplement incorporating the base shelf prospectus relating to the offering may be obtained by either contacting the underwriters, by accessing the SEC website, http://www.sec.gov/, or by accessing the website maintained by the Canadian securities regulatory authorities, SEDAR, at http://www.sedar.com/.

    In the United States from: Dahlman Rose & Company, LLC Attn: Prospectus Dept. 142 West 57th Street 18th Floor New York, NY 10019 Phone: 212-702-4521 Fax: 212-920-2952 Email: ECM@dahlmanrose.com In Canada from: Wellington West Capital Markets Inc. Attn: Scott Larin 145 King Street West, Suite 700 Toronto, Ontario M5H 1J8 Phone: 416-640-4893 Fax: 416-640-4946 Email: slarin@wwcm.com

    This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the final prospectus supplement, the base prospectus or the Company's shelf registration statement. A registration statement relating to the securities has been filed with the SEC and became effective April 30, 2009. A final prospectus supplement relating to the offering has been filed with the SEC. A base shelf prospectus has been filed with the securities regulatory authorities in certain provinces in Canada and a final prospectus supplement was filed with such regulatory authorities.

    About Vista Gold Corp.

    Since 2001, Vista has acquired a number of gold projects with the expectation that higher gold prices would increase their value. Vista has taken steps to advance the Paredones Amarillos gold project located in Baja California Sur, Mexico, towards production. These steps include the completion of a definitive feasibility study, the purchase of long delivery processing equipment items, and the purchase of land for the processing facilities, related infrastructure and the desalination plant. The results of a preliminary economic assessment completed in 2009 on the Mt. Todd gold project in Australia are encouraging and Vista is undertaking other studies to advance the project, with the completion of a preliminary feasibility study targeted for the fourth quarter of 2009. Vista's other holdings include the Guadalupe de los Reyes gold project in Mexico, Yellow Pine gold project in Idaho, Awak Mas gold project in Indonesia, and the Long Valley gold project in California.

    For further information, please contact: Vista Gold Corp. Attn: Greg Marlier 7961 Shaffer Parkway, Suite 5 Littleton, Colorado 80127 Phone: 720-981-1185 Fax: 720-981-1186 Email: gmarlier@vistagold.com

    This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Vista expects or anticipates will or may occur in the future, including such things as the anticipated closing of the offering, the expected net proceeds from the offering, and the anticipated use of proceeds. When used in this press release, the words "optimistic", "potential", "indicate", "expect", "intend", "hopes," "believe," "may," "will," "if" and similar expressions are intended to identify forward-looking statements and forward-looking information. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Vista to be materially different from any future results, performance or achievements expressed or implied by such statements. Such factors include, among others, uncertainty of market response to the offering, the net proceeds from the offering, the future use of proceeds, risks relating to cost increases for capital and operating costs including cost of power; risks relating to delays at Vista's projects; risks of shortages of equipment or supplies; risks relating to fluctuations in the price of gold; the inherently hazardous nature of mining-related activities; uncertainties concerning resource estimates; potential effects on Vista's operations of environmental regulations in the countries in which it operates; risks due to legal proceedings; risks relating to political and economic instability in certain countries in which it operates; risks related to repayment of debt; risks related to increased leverage and uncertainty of being able to raise capital on favorable terms or at all; as well as those factors discussed in Vista's latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q and other documents filed with the U.S. Securities and Exchange Commission and Canadian securities commissions. Although Vista has attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements and forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Except as required by law, Vista assumes no obligation to publicly update any forward-looking statements or forward-looking information; whether as a result of new information, future events or otherwise.

    Vista Gold Corp.

    CONTACT: Greg Marlier of Vista Gold Corp., +1-720-981-1185, Fax,
    +1-720-981-1186, gmarlier@vistagold.com

    Web Site: http://www.vistagold.com/




    Microsoft and M-Com Deliver Mobile Payments Solution GloballyLeading mobile banking software vendor leverages the Microsoft platform to deliver the most flexible and scalable mobile payments solution.

    HONG KONG, Sept. 15 /PRNewswire-FirstCall/ -- Microsoft Corp. and M-Com today announced a solution offering that provides banks and payment processors with industry-leading mobile payments functionality -- creating more opportunities for banks to offer mobile payments services to their customers and maximize their revenue opportunities. This solution clearly demonstrates that consumer choice and deployment flexibility for banks are key to the success of global mobile payments solutions for the financial services industry. The announcement was made at Sibos 2009, the industry's premier global financial services forum.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

    Using Microsoft technologies, M-Com BankAnywhere provides a complete end-to-end mobile payments solution for the banking industry worldwide. The comprehensive solution provides best-practice security and risk management capabilities, ensuring that banks can effectively manage the exposure of their brands and services in the emerging market for mobile technology. As a fully integrated solution, it reduces the total cost of ownership (TCO) for the mobile channel for banks.

    A Microsoft Gold Certified Solution Developer, M-Com supports BankAnywhere across the globe and, in doing so, utilizes Microsoft resources and best practices in deploying BankAnywhere. The use of standard Microsoft technology, including Windows and Microsoft SQL Server, as well as Internet Information Services (IIS), allows enterprise users of BankAnywhere to benefit from existing industry-standard technology management tools and practices.

    "Consumers today have many options and channels, requiring financial services firms to engage customers through a highly personalized, connected experience -- consistent across all touch points -- that builds strong relationships, creates customer intimacy and boosts loyalty," said Susan Hauser, vice president of Worldwide Financial Services at Microsoft. "Today's announcement underscores our efforts to provide multichannel integration that allows financial institutions to benefit from mobile and new media channels as part of the overall connected experience. Our alliance with M-Com expands our partner ecosystem for payments and mobile solutions and further validates our leadership position as a provider of payment processing platforms."

    Financial institutions, facing declining revenue from traditional credit cards, are looking to use mobile payments to replace cash-dominated lower value payments to generate new revenue streams. This is important for banks and retailers, as cash handling is both expensive and a security risk.

    "With the increasing adoption of mobile applications running on smartphones, the mobile channel can no longer be ignored by banks," said Red Gillen, senior analyst at Celent. "Mobile payments continue to be at the top of the list of applications that will entrench mobile financial services in consumers' daily lives, propelling it into the mainstream. As banks look to invest in this strategic area, vendors that can provide solutions which go beyond simple mobile banking informational services to address other value-added services such as bill payment will be the ones that come out on top."

    For most financial institutions, paper-based payment transactions are expensive to support and offer few opportunities for differentiation. While the cost metrics associated with processing checks and cash payments vary substantively across jurisdictions, financial institutions, and payment types, it is well understood that electronic payments -- including those carried out through mobile phones -- have a direct positive impact on for the cost structures of payers, payees and financial institutions alike.

    Global consumer demand also is helping to propel this migration. The growing ubiquity of mobile phones and their increasing multifunction capabilities make these devices a compelling candidate for replacing a physical wallet.

    "It is clear that consumers in Asia and around the world have an insatiable demand for mobile financial services, especially payment transactions," said Adam Clark, CEO of M-Com. "Banks must engage their customers and prospects in the mobile channel in the short term to ensure they profit from sustainable revenues and key customer segments that are adopting these services."

    As prominent examples, Bangkok Bank and KeyBank both recently selected a mobile financial services solution that leverages the M-Com BankAnywhere platform. The institutions chose Mobile Money from Fiserv Inc., which was launched in conjunction with M-Com in September 2008. Fiserv, a partner of Microsoft and M-Com, is the leading global provider of financial services technology solutions.

    "The uptake of this cutting-edge consumer banking technology demonstrates a significant shift in how banks across the world connect with their customer," said Karen Campbell, executive vice president at Bangkok Bank. "Customers in Asia are at least as demanding as their counterparts in Europe and the U.S. -- they need the portable banking tools to complement their busy, highly mobile lifestyles."

    The mobile payment experience should be delivered across multiple mobile devices, manufacturers and cellular phone carriers to accommodate the personal preferences of the target audience: the consumer. This is the only way that choice can be extended across global markets. BankAnywhere on the Microsoft platform addresses these business imperatives by delivering the following:

    -- New revenue opportunities from payment and value-added transactions -- Cost elimination through a proven ability to move customers to lower-cost, self-service channels -- Differentiation and control over the bank's mobile channel and the user experience they provide to customers

    "We needed a product that would scale to a large number of users and could be extended to meet the diverse needs of Key's multiple lines of business and client segments," said Allison Landers, senior vice president, Virtual Banking, KeyBank. "Mobile banking is a strategic opportunity area for banks. By adopting the M-Com BankAnywhere platform for SMS, we're providing our clients a strong first step into mobile banking with a seamless and compelling user experience."

    Mobile banking services are the best way to open up a mobile-centric relationship with consumers. Open loop payment mechanisms, choice of payment execution models, and interoperability across devices are essential to delivering the optimal experience. With its ecosystem of payments partners, including M-Com and Fiserv, Microsoft is helping banks through the complexity and challenges of mobile financial services.

    About Microsoft in Financial Services

    Microsoft's Financial Services Group provides software that helps financial firms transform the customer, employee and operations experience so they can maximize opportunities for increased market share and profitability. Microsoft software helps empower people and IT staff within financial firms -- and across key focus areas such as advisor platforms, channel renewal, insurance value chain, enterprise risk management and compliance, and payments. Through a combination of Microsoft- and partner-provided solutions, customers enable their employees to turn data into insight, transform ideas into action and turn change into opportunity.

    More information about Microsoft's Financial Services Group can be found at http://www.microsoft.com/financialservices.

    About M-Com

    Headquartered in Atlanta, GA, M-Com is an international mobile banking and payments solution provider working with banks and transaction processors in North America, Australasia, Europe, the Middle East and Asia. M-Com's core proposition is centered on delivering world class adoption and revenue metrics from mobile payment services.

    For more information, visit http://www.mcom.co.nz/. About Microsoft

    Founded in 1975, Microsoft is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

    Photo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO
    http://photoarchive.ap.org/
    PRN Photo Desk photodesk@prnewswire.com Microsoft Corp.

    CONTACT: Serge van Dam of M-Com, +1-678-369-0602,
    serge.vandam@mcom.co.nz; or Wendy Grover of Microsoft Corp., +1-425-705-7609;
    or Chanda Gathani of Metia, +44 795 11 63615, chanda.gathani@metia.com, for
    Microsoft Corp.

    Web Site: http://www.microsoft.com/
    http://www.mcom.co.nz/




    CBp Carbon Industries Announces Pre-Commercial Production for Its First Commercial Plant in Cyprus

    BRATISLAVA, Slovakia, Sept. 15 /PRNewswire-FirstCall/ -- CBp EU Headquarters - CBp Carbon Industries, Inc. ("CBp" or "the Company") is pleased to provide shareholders with an update in its affairs, particularly its progress of plant construction and technology development.

    We are pleased to advise that CBp has reached an exciting milestone in its history by completing the world's largest state-of-the-art operational tire pyrolysis plant. We are proud to advise that our new completed first generation commercial plant in Cyprus is in pre-production and receiving tipping fee revenues. The new plant is just finishing 'hot tests' (processing scrap tires) and will enter continuous commercial operations in Q4. Our plant will commence commercial deliveries of product in Q4, starting with steel and oil deliveries first, with our Carbon Green (our substitute carbon black patented product) reaching full output in Q1 2010 when we have completed our pelletizing process for Carbon Green delivery.

    We are very pleased with the capabilities and dedication of our development team, headed by Peter Tsantrizos who became our Chief Technology Officer and COO early in 2008 when our then CTO, Mr. Jack Fader, suffered serious health problems. Mr. Fader was unable to assist in the Cyprus plant development and this was accomplished entirely by our team under the leadership of Mr. Tsantrizos. However, Mr. Fader was able to continue to provide some technical advice for a period of time in the area of new patent filings and completing transfer of all patents for the technology to our company in 2008/early 2009. Accordingly all patents in respect to our technology including pyrolysis, Carbon Green production and Carbon Green applications belong wholly to CBp.

    Our team overcame all challenges in building the Cyprus plant and have substantially improved our technology with installation of a new horizontal reactor, improved flow processes and improved plant design and configuration. As examples of the skills of our team instead of sub-contracting out installation of major equipment, as initially planned, our team managed the completion of the reactor installation and the fulfilling of electronic and computer control systems themselves thereby developing these areas of expertise within our Company team. Our team's meetings with our main customer, Triputra Group, in Indonesia, to coordinate our production of Carbon Green with their quality requirements (we signed a 200,000 tonne per year 'take or pay' contract for Carbon Green with them) resulted in a decision that we would not master-batch in Cyprus but would pelletize our Carbon Green. This saved us 2 million Euros for masterbatching facilities in Cyprus and will substantially drop our processing costs. However as no one had developed a pelletizing process for our type of product, our team rose to the task and developed a customized pelletizing process for our product. The prognosis for our Cyprus plant, and our new plants being planned, has also greatly increased with the EU's recent requirement that all tires contain a minimum 5% recycled material. This significantly enhances the value of our technology which has been chosen by the EU as the only qualifying/best available technology to meet EU strict tire recycling standards. The result is that our customers are more anxious than ever for access to our products and this seems to insulate our product prices from the recent swings in commodity prices and therefore has created stronger demand.

    Although we have now built two plants (one pilot and one commercial), we are effecting due diligence on a third site, have effected substantial research, conducted extensive development of products and opportunities and borne all the other costs of a major world-wide corporate endeavor, we still have substantial cash left in our treasury and no debt even though we have done little new finance in approximately two years. The Company has now commenced seeking to list the company on a more senior US exchange to better reflect its advanced stage of development.

    John Novak stated "We are extremely pleased with the capabilities of our development team and their ability to deliver on the Company's rapid growth plans. We are confident that we will make a difference in creating value for our stock holders and contributing materially to making this a greener and more sustainable world."

    John Novak On Behalf of the Board of Directors and the Company About CBp Carbon Industries, Inc.

    CBp Carbon Industries, Inc. is a global company that develops and commercializes our advanced technologies that enrich the environment, the countries and communities in which we operate, and our shareholders. Our primary focus is tire recycling with our patented technology which permits 100% recycling of tires and scrap rubber into commercially viable marketable components of steel, oil and CBp Carbon Green(TM), which is a tested substitute for replacement of carbon black in tire and rubber manufacturing.

    Since 2006, European Union directives have banned scrap tires, shredded tires and tire residues from being landfilled and stockpiled. An EU scientific team, working with the European Union Cooperative Research Recycle Tire (CRAFT) project, selected CBp Carbon Industries technology as the "best available technology" for meeting CRAFT's recycling objectives.

    For more information, please contact: info@cpbcarbon.com Web address: http://www.cbpcarbon.com/

    FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding CBp Carbon Industries, Inc. and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where CBp Carbon Industries Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. CBp Carbon Industries Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    CBp Carbon Industries, Inc.

    CONTACT: CBp Carbon Industries, Inc., + 1-778-996-6400,
    info@cpbcarbon.com

    Web Site: http://www.cbpcarbon.com/




    Multiplied Media's Poynt mobile local search application surpasses 1,000,000 users

    CALGARY, Sept. 15 /PRNewswire-FirstCall/ -- Multiplied Media Corporation (TSX:V MMC), an award-winning, Calgary-based provider of mobile local search services, is pleased to announce its 1,000,000th user for the Poynt application.

    "We are extremely pleased that our users have come to trust Poynt as their go-to application for mobile local search," stated Andrew Osis, CEO, Multiplied Media. "The increase we have seen in average monthly searches per user reinforces our decision to add people and restaurant search to Poynt. With the continued adoption of our latest release by the existing user base and the anticipation of our previously announced version for iPhone, we expect continued user growth, and as a result, growth in average searches per user which in turn contributes to revenue generation."

    Poynt is a free** local search application that delivers business, people, movie and restaurant listings by keyword and location. The application is available for the BlackBerry(R) Pearl(TM) and BlackBerry(R) Curve(TM) series smartphones, as well as the BlackBerry(R) Bold(TM), BlackBerry(R) Storm(TM) and BlackBerry(R) Tour(TM) smartphones and takes advantage of capabilities including locates by GPS* and cell-site, click-to-call, click-to-map and click-to-browse-website. Poynt is available to BlackBerry smartphone owners in Canada, the United States, Germany and the United Kingdom. The latest version of Poynt is available for download on BlackBerry App World(TM) (http://www.blackberry.com/appworld) or by visiting http://m.mypoynt.com/ from your BlackBerry(R) Browser.

    * Requires a GPS-enabled BlackBerry smartphone. ** Wireless charges may apply. Please check with your wireless service provider. About Multiplied Media Corporation ----------------------------------

    Multiplied Media (http://www.multiplied.com/) has developed the award-winning application Poynt (http://www.mypoynt.com/), the mobile local search service available over BlackBerry smartphones. Through agreements with directory and vertical content providers in Canada, the United States and Europe, Poynt simplifies finding and connecting with businesses, retailers and events wherever and whenever it is most convenient for the consumer. Headquartered in Calgary, AB, Canada, Multiplied Media trades on the TSX Venture Exchange under the symbol MMC.

    Forward-looking Statements --------------------------

    This news release contains forward-looking statements relating to the anticipated impact on user numbers and revenues relating to the adoption of the Poynt application as well as development for the iPhone, timing of the iPhone release, potential revenue generation and other statements that are not historical facts. Such forward-looking statements are subject to important risks, uncertainties and assumptions. The results or events predicated in these forward-looking statements may differ materially from actual results or events. As a result, you are cautioned not to place undue reliance on these forward-looking statements.

    These forward-looking statements are based on certain key assumptions regarding, among other things: future technological developments; the cost of expanding product lines; the impact of increasing competition; the continuity of existing business relationships; conditions in general economic and financial markets; and our ability to obtain financing on acceptable terms. Material risk factors that could cause actual results to differ materially from the forward-looking information include, but are not limited to: the deteriorating economic and market conditions that could lead to reduced spending on information technology products; competition in our target markets; potential capital needs; management of future growth and expansion; the development, implementation and execution of the Company's strategic vision; risk of third-party claims of infringement; protection of proprietary information; customer acceptance of the Company's existing and newly introduced products; and the success of the Company's brand development efforts; risks associated with strategic alliances; reliance on distribution channels; product concentration; need to develop new and enhanced products; potential product defects; our ability to hire and retain qualified employees and key management personnel; and risks associated with changes in domestic and international market conditions and the entry into and development of new markets for the Company's products.

    The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on expectations of, or statements made by, third parties in respect of the forward looking statements identified above.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    The BlackBerry and RIM families of related marks, images and symbols are the exclusive properties and trademarks of Research In Motion Limited.

    Multiplied Media Corporation

    CONTACT: Andrew Osis, CEO Director, Multiplied Media Corporation,
    (403) 444-4102, andrew.osis@multiplied.com; MEDIA CONTACT: Margaret
    Glover-Campbell, Director, Communications, Multiplied Media Corporation, (403)
    444-4105, margaret.glover-campbell@multiplied.com




    Payless ShoeSource Unveils Spring '10 Designer Collections on the Runway at New York Fashion WeekUnique Shoe and Handbag Designs Inspired by Venice Beach, French Rock Band the Plastiscines, and Mediterranean Luxury Hit the Runway at Designers' Shows: Lela Rose, Stacey Bendet and Christian Siriano

    NEW YORK, Sept. 15 /PRNewswire/ -- Payless ShoeSource is continuing to make it possible for consumers to indulge in affordable runway style with the unveiling of its designer labels for spring here at New York Fashion Week. Fashion fans can look forward to amazing designer style as Payless, well-known for democratizing fashion in footwear and accessories, and its Guest Designers - Lela Rose, Stacey Bendet, and Christian Siriano -- unveil the Payless Spring '10 Designer Collections in true "high-low" fashion on the runway.

    (Photo: http://www.newscom.com/cgi-bin/prnh/20090915/CG76456)

    Payless designer collections are among the most widely distributed designer footwear labels in America today. Payless Spring '10 designer footwear and handbag collections will be available in stores in February with average price points under $40 an item. In the meantime, shoppers can spice up their fall wardrobes with the Fall '09 designer labels from Payless, including Abaete for Payless, Lela Rose for Payless, alice + olivia for Payless, and Christian Siriano for Payless all available now in select Payless stores nationwide and Payless.com.

    "We are thrilled to see Payless shoes strut the runway again at New York Fashion Week with Lela Rose, Stacey Bendet, and Christian Siriano," said LuAnn Via, CEO and president of Payless ShoeSource. "The nation's premier fashion event is a phenomenal stage to showcase the talent and distinct design aesthetic of each of our Payless guest designers. For the Spring season there is a range of inspirations from old Venice beach to the Mediterranean, along with a dash of Parisian indie rock. The unique designs from each designer is truly amazing, and we are always excited to see it all come together when the Payless shoes are paired with the designer's ready-to-wear (RTW) and hit the runway."

    Unveiled at the Lela Rose runway show, the Spring '10 Lela Rose RTW collection is inspired by old Venice Beach surf and scuba wear with its body-hugging shapes, details and seaming. The color palette of artist Alex Katz sets the tone. With a nod to Lela's RTW, the shoe collection -- Rose's 11th Lela Rose for Payless seasonal line -- includes six styles featuring her signature use of fabric and mixed materials coupled with Katz-splashes of color including citrine, bright navy, sea grass and magenta. The unique silhouettes consist of sculpted wedge heels, criss-cross straps, and peep-toe mary jane details.

    Previewed at a special presentation event, Stacey Bendet's Spring '10 RTW collection for alice + olivia is inspired by the Plastiscines, a French all-girl rock band. The band's mix of indie rock and Parisian chic is evident in shoes, which evoke both a whimsical and sleek sensibility. This is Bendet's sixth line for Payless and includes such silhouettes as a platform pump, tall slouchy boot, gladiator-style flat sandal and platform heel. Details such the use of form-fitting "wet-suit" material, a "sandalized" upper design combined with a tall boot, and side-cut-out designs portray a strong interplay of structure and sexiness.

    Fashion designer Christian Siriano, well-known also as the winner for Project Runway's Season Four, showcased his Spring '10 footwear and accessories collection with Payless on the runway. The line complements Siriano's Spring '10 RTW collection inspired by the notion of luxurious Mediterranean travel. Rich colors like fuchsia, blue and orange are amped up to evoke the glorious coastal sunset taken in while yachting. Khakis, nudes and blushes are present, as well as a unique printed fabric used heavily in the collection. The fabric print was created using an aerial photograph of the intricate Italian coast line that has been flipped, modified, repeated and saturated with volcanic and oceanic colors. The five shoe silhouettes and accompanying handbags -- Siriano's second line for Payless -- mirror this inspiration and are truly dramatic works of art conveying strength and textural tribal themes with the use of mottled prints and hides combined with raw metal sequins and details.

    Celebrity Sightings in Payless Designer Shoes

    Many celebrities came out to the shows supporting the designers and decked out in the designer's designs from head-to-toe -- as well as Payless designer shoes.

    About Payless Designer Collections

    Payless is on a mission to democratize fashion and design in footwear and accessories. The Payless Designer Collections - seasonal lines of original footwear and handbags created by New York fashion designers and hot-off-the-runway - are a key piece of that strategy.

    Payless' designer collections are among the most broadly distributed designer footwear labels available in the United States today. Payless Guest Designers include Lela Rose and the Lela Rose for Payless and Unforgettable Moments(TM) by Lela Rose labels, Stacey Bendet with alice + olivia for Payless, Christian Siriano and Christian Siriano for Payless and style icon Patricia Field with Patricia Field for Payless capsule collections. This select group of fashion designers and stylists create designer footwear and accessory collections for Payless featuring the latest runway and red carpet styling details. Each collection is unique and reflective of the designer's signature style. For more information about Payless at New York Fashion Week and the company's Guest Designers, please see paylessontherunway.com.

    About Payless & Collective Brands, Inc.

    Payless ShoeSource, Inc., a unit of Collective Brands, Inc., is the largest specialty family footwear retailer in the Western Hemisphere and is dedicated to democratizing fashion and design in footwear and accessories and inspiring fun, fashion possibilities for the family at a great value. As of the end of second quarter 2009, the company operated more than 4,500 stores. In addition, customers can buy shoes over the Internet through Payless.com at http://www.payless.com/.

    Collective Brands, Inc. is a leader in bringing compelling lifestyle, fashion and performance brands for footwear and related accessories to consumers worldwide. The company operates three strategic units covering a powerful brand portfolio, as well as multiple price points and selling channels including retail, wholesale, ecommerce and licensing. Collective Brands, Inc. includes Payless ShoeSource, focused on democratizing fashion and design in footwear and accessories through its more than 4,500-store retail chain, with its brands American Eagle(TM) by Payless, Airwalk , Dexter , Champion and designer collections Christian Siriano for Payless, Abaet for Payless, Lela Rose for Payless and alice + olivia for Payless, among others; Stride Rite, focused on lifestyle and athletic branded footwear and high-quality children's footwear sold primarily through wholesaling, with its brands including Stride Rite , Keds , Sperry Top-Sider , Robeez , and Saucony , among others; and Collective Licensing International, the brand development, management and global licensing unit, with such youth lifestyle brands as Airwalk , Vision Street Wear , Sims , Lamar and LTD . Information about, and links for shopping on, each of the Collective Brand's units can be found at http://www.collectivebrands.com/.

    AMERICAN EAGLE BY PAYLESS IS NOT AFFILIATED WITH AMERICAN EAGLE OUTFITTERS

    Photo: http://www.newscom.com/cgi-bin/prnh/20090915/CG76456
    http://photoarchive.ap.org/
    AP PhotoExpress Network: PRN23
    PRN Photo Desk, photodesk@prnewswire.com Payless ShoeSource, Inc.

    CONTACT: Mardi Larson, +1-612-928-0202, mardilarson@payless.com, for
    Payless ShoeSource, Inc.

    Web Site: http://www.collectivebrands.com/
    http://www.payless.com/

    page 1     page 2     page 3     page 4     page 5     page 6     page 7     page 8     page 9     page 10     page 11    

    News archive of December 2017
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 



    News Archives of September 2009
    1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31  

    News Archives other dates
  •  
    0-C     D-L     M-R     S-Z